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Abstract: In recent years, mounting scientific evidence has emerged regarding the evaluation
of the putative correlation between the gut microbiota composition and the presence of chronic
non-communicable diseases (NCDs), such as diabetes mellitus, chronic kidney disease, and arterial
hypertension. The aim of this narrative review is to examine the current literature with respect
to the relationship between intestinal dysbiosis and the insurgence/progression of chronic NCDs,
analyzing the physiopathological mechanisms that can induce microbiota modification in the course
of these pathologies, and the possible effect induced by microbiota alteration upon disease onset.
Therapy based on probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplant can
represent a useful therapeutic tool, as has been highlighted on animal studies. To this moment,
clinical studies that intended to demonstrate the beneficial effect induced by this kind of oral
supplementation on the gut microbiota composition, and subsequent amelioration of signs and
symptoms of chronic NCDs have been conducted on limited sample populations for a limited
follow-up period. Therefore, to fully evaluate the therapeutic value of this kind of intervention,
it would be ideal to design ample population; randomized clinical trials with a lengthy follow
up period.
Keywords: chronic non-communicable diseases; gut microbiota; prebiotics; probiotics;
synbiotics; dysbiosis
1. Introduction
The human microbiota is a complex collection of microorganisms that colonizes the human body
at the cutaneous, oral, respiratory, gastrointestinal, and genitourinary tract. The estimated weight
of the microbiota is about 1.5 kg, and it mainly includes bacteria, but also viruses, fungi, protozoa,
and archaea. In the gut, there are about one trillion bacteria (a value ten times higher respect to the
number of human cells), comprising from 500 to 1000 species [1].
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Even if historically the ratio between bacterial and human (B/H) cells was hypothesized to be
10:1, this has been recently criticized [2]. A study has proposed that in reality the B/H ratio is of 1:1.
Such data has been deduced from the re-evaluation of the number of cells and bacteria in the human
body by using new DNA analysis techniques, magnetic resonance imaging (MRI), to correctly estimate
the weight of each organ, and through the revision of scientific literature pertinent to this subject [3].
The “microbiome”, meaning the genome of the microbiota combined with its environmental
interactions [4], includes more than 3 million genes and is 150 times the size of the human genome.
The complexity and interest in the microbiota led to the foundation in 2008 of the “MHP—Microbiome
Human Project”, which was aimed to identify, characterize, and classify the microorganisms of the
human microbiota [5].
The human microbiota plays a key role in the immune system maturation, metabolism of lipids,
glucose, and bile acids, and in the defense against pathogens through the competition for space and
nutrients, by activating the host immune system and by “priming” immune cells [6].
This extended microbial community can be considered as a highly dynamic organ, which is
sensitive to environmental insults and modifies its composition over the host’s lifespan. Its structure
and activity are influenced by multiple factors that make it a unique system, which varies from
individual to individual, Figure 1 [7].
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NCDs, chronic non-communicable diseases.
In the real of the microbiota a “core” has been identified, represented by a series of taxa constantly
present in healthy subjects and absent in pathologic subjects, suggesting that the absence of such taxa
may characterize dysbiosis [8]. However, successive studies have reconsidered this hypothesis because
of a certain degree of taxonomic variation between heathy individuals [8,9].
A ne hypothesis has identified a “healthy functional core”, which can be described as a complex
of metabolic and molecular functions carried out by the microbiota but not necessarily linked to the
same microorganisms in different individuals [10].
Nutrients 2019, 11, 1073 3 of 35
The mode of delivery influences the neonatal composition of the gut microbiota. Neonates born
vaginally have microbes similar to those located in the vaginal maternal microbiota. Whilst those
delivered by caesarean section have a typically cutaneous microbiota, consisting mainly of Staphylococcus
and Propionibacterium spp. [11] and microbes from the hospital environment [12].
In infants, particularly during the first year of life, delivery mode has been hypothesized to
affect immunological functions and gut microbiota composition. Newborns delivered by caesarean
section have a reduced number of bacterial cells counts in fecal samples and a large number of
antibody-secreting cells [13]. Feeding type modality in infants is an ulterior factor in microbiota
modulation. Some studies have shown there is a difference in the gut microbiota composition between
breast fed infants and formula fed infants [14,15]. The latter, present altered bacterial abundance
particularly skewed towards the family of the Peptostreptococcaceae that contains Clostridium difficile,
which is commonly associated with gastrointestinal and autoimmune pathologies.
Numerous studies have shown how breast-feeding is correlated to a reduced risk of developing
chronic degenerative pathologies such as diabetes mellitus (DM) and obesity, and chronic inflammatory
intestinal pathologies. Moreover, breast-feeding confers protection towards respiratory and
gastrointestinal infections, and allergies [16,17].
Dietary habits, which are closely related to geographical factors, ethnicity, and food culture represent
an important element for the constitution and function of the gut microbiota [18]. With regards to
ethnicity, a study by Deschasaux et al. [19] conducted on 2084 healthy subjects, all resident in
Amsterdam but belonging to six distinct ethnic groups, has shown that even if all the subjects lived in
the same city, they still presented varying gut microbiota composition, which could be attributed to
their different ethnicities. Therefore, the observed differences, characterized by varied alpha-diversity
and interindividual variations, are independent of metabolic health and are partly explained by
characteristics linked to ethnicity such as alimentary habits, life style, and socio-demographic
factors [20].
A study by De Filippo et al. [21] compared the fecal microbiota of European Union (EU) children to
that of children from the rural African village of Burkina Faso (BF). The BF children diet is characterized
by high intake of fiber. BF children showed a significant increase in Bacteroidetes and reduction in
Firmicutes, with an exclusive bacterial richness from the genus Prevotella and Xylanibacter, which can
hydrolyze cellulose and xylan, completely absent in EU children. This suggests that the gut microbiota
is influenced by polysaccharide-rich dietary content of BF children, allowing them to maximize energy
intake from fiber-based diet [21].
Bacterial metabolites differ from those generated by enzymatic processes in humans, as bacterial
reactions occur under anaerobic conditions and are constituted mainly by reductive or hydrolysis
reactions. Studies conducted on the metabolism of polyphenols in the gut microbiota have allowed
the understanding of functions performed by these compounds, and their possible health effects
in humans [22–24]. Nowadays, the literature has highlighted the possible metabolic pathways
of polyphenols by intestinal bacteria and examined their diet related metabolism [25]. In the
pathophysiological mechanism of many pathological conditions, the alteration of the gut microbiota
plays an essential role. In fact, the balance between the host’s immune system and the gut microbiota
composition is fundamental in the maintenance of a healthy status [26].
Amongst foods able to influence gut microbiota composition, polyphenols deriving from red
wine have particular importance [27,28]. Whereby, their daily consumption for only four weeks
significantly enhanced the number of Enterococcus, Prevotella, Bacteroides, and Bifidobacterium
genera and Bacteroides uniformis, Eggerthella lenta, Blautia coccoides, and Eubacterium rectale species [22].
Recent studies have also shown that resveratrol can positively modulate gut microbiota
composition, ameliorating glucose tolerance in a murine model of obesity [28–30].
It is therefore, deduced that diet plays a fundamental role in modulating the composition of the
gut microbiota, becoming an active part in some disease pathogenesis.
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Although the association between the onset of metabolic pathologies and the alteration of the
Firmicutes to Bacteroides (F/B) ratio relationship remains uncertain, recent studies have highlighted
a correlation between the presence of Akkermansia and Lactobacillus genera with central obesity and
fasting hyperglycemia [31,32].
Polyphenols, oligo-, and polysaccharides seem to be able to favor the growth of beneficial bacteria
and inhibit that of pathogenic species [22,33,34].
The health effects of polyphenols, depends on their bioavailability. Amongst polyphenols,
minor polar compounds from extra virgin olive oil, in particular hydroxytyrosol (HT), play a pivotal
role in modulating the gut microbiota composition [35]. Since the concentration of HT in the body is
reduced, it is hypothesized that HT may have direct effects on the gastrointestinal system, before its
absorption. Therefore, the bioavailability and the beneficial effects of polyphenols on the host
are related to their transformation by specific pathways via esterase, glucosidase, demethylation,
and decarboxylation activities in gut microbiota [36].
Age is another factor that influences the composition of the human microbiota. At birth,
the variability of the microbiota is lower because the diet is solely comprised of the mother’s milk.
With time and the introduction of an ample variety of foods, the human microbiota adapts by varying
and increasing its bacterial composition in order to metabolize as many foods as possible [37].
Literature evidence shows that a variety of age-related conditions such as physical frailty,
and pathologies such as C. difficile colitis, vulvovaginal atrophy, colorectal carcinoma, and cardiovascular
(CV) disease can be linked to microbiota alterations. As a future prospect, microbiota manipulation in
elders could be an innovative therapeutic strategy to counteract the evolution/progression of age-related
comorbidities [38].
The effect of antibiotics on the human microbiota composition is the most studied drug type
interaction. Antibiotic therapies are not only effective against pathogenic microorganisms but also
against the host associated microbial communities in the gut, and act by reducing the variability of
the intestinal microbiota. Löfmark et al. [39] showed that even short-term antibiotic administration
(one week of clindamycin) could cause long-term alterations in the commensal microbiota of healthy
subjects, detectable up to two years after antibiotic administration.
Physical activity is another important factor that influences the composition and the function of the
gut microbiota, by having a beneficial impact on it. A study by Clarke et al. [40], conducted on
professional rugby players, demonstrated that physical exercise increases the alpha-diversity
(expression of the number of species present in relation to their relative abundance and correlated
to the health status of the subject) of gut microorganisms, which is significantly correlated with
creatine kinase (CK) plasmatic levels and protein intake. This study strengthens the hypothesis that
physical activity has a positive influence on the microbiota composition, by having an impact on its
alpha-diversity [5,41]. In the same study, the authors demonstrated that athletes with lower body mass
index (BMI) had significantly higher abundance of the species Akkermansia muciniphila. The latter is
a gram-negative bacterium, which is able to degrade mucin and its presence is inversely correlated
with obesity and metabolic disorders in mice and humans [42,43]. A. muciniphila carries out a beneficial
function on the human organism because it is involved in increasing the thickness of the intestinal
mucosa, bettering its tropism and protective function against pathogens [44].
Moreover, by degrading mucin it provides energetic substrates to other commensal species present
in the gastrointestinal lumen [45].
The gut microbiota composition is usually characterized by bacterial members of the Bacteroidetes
and Firmicutes phyla [46]. However, an important range of variation in the taxa present in the gut and
interindividual variability in microbial composition has been observed, it has been supposed that the
gut microbiota of most individuals can belong to one of three possible variants or “enterotypes” based
on the dominant genera (Bacteroides, Prevotella, or Ruminococcus) [47]. These variants may in fact be
more appropriately characterized as a ratio of the relative abundance of Bacteroides and Prevotella,
with the Ruminococcus enterotype comprised into the Bacteroides group [48].
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In reality, from latest studies, it has emerged that the most correct term to describe the gut
microbiota composition is not via the characterization of the dominant enterotype, but rather via
the evaluation of the concentration gradient of different microbial species along the gastro-intestinal
tract [49,50].
Quantitative and qualitative alteration of the gut microbiota composition is termed “dysbiosis”.
In recent years the correlation between altered microbiome and pathologies, including different systems
of the human organism, ranging from the gastrointestinal tract to the genitourinary tract up to the
central nervous system, have received increasing interest [51].
Dysbiosis has been associated with the onset of many inflammatory, non-inflammatory,
and infectious diseases such as the inflammatory bowel disease, the metabolic syndrome, cancer,
autoimmune conditions, and C. difficile infection [52].
In this review, we analyze the current literature on the correlation between the composition of
human microbiota and the onset and progression of chronic non-communicable diseases (NCDs),
specifically: chronic kidney disease (CKD), DM, and arterial hypertension (HTN), evaluating both
animal and human studies. Biomedical studies are largely based on murine models, since the anatomy
and the physiology are quite similar to that of humans. This is particularly true for the gastrointestinal
apparatus; however, it must be noted that there are also some differences correlated to different diet,
body composition and metabolic requirements [53].
Regarding microbiota composition, the two major phyla are common to both humans and rats
(Bacteroidetes and Firmicutes) [54–56].
However, on a more detailed analysis of the taxonomic classification of the gut microbiota,
about 85% of bacteria genera present in the rat cannot be found in humans [50].
Murine models appear as useful tool to comprehend mechanisms that correlate microbiota related
pathologies, and allow scientist to perform research that would not conductible in humans, even if the
results obtained are not always translatable because of species specific variations.
2. Methods
Current literature covering the impact of gut microbiota on onset of NCDs is analyzed and
contextualized in this review. Specifically, research has been conducted on Medline (Pubmed) and
Scopus. Such research examines studies published until January 2019 utilizing the words: “microbiota”,
“gut microbiota” alone or in combination with “kidney”, “CKD”, “diabetes”, “hypertension”,
“prebiotic”, “probiotic”, “synbiotic”, “postbiotic”, “fecal transplant”.
3. Gut Microbiota and Chronic Kidney Disease
Already in the 60s, a study conducted by Einheber et al. [57] demonstrated how the survival
of germ-free nephrectomized mice was superior to conventionally raised nephrectomized mice.
This pioneering study paved the way for further studies on the microbiota-kidney axis. Amongst the
most recent studies conducted on humans one of particular interest Aranov et al. [58], which showed
how colectomized hemodialysis (HD) patients have lower plasma levels of uremic toxins compared to
HD patients with an intact colon, these data suggest the close relationship between the production of
uremic toxins and gut microbiota.
Over the years, several studies have been conducted to characterize the gut microbiota. The first
studies [5] were based on classic microbiological culturing techniques, whilst, recently, advances have
been made thanks to the sequencing of either total DNA or 16S ribosomal RNA-genes. Uremia is
a condition able to alter the gut microbiota composition, leading to dysbiosis. In CKD, there is
a subversion of the normal intestinal balance resulting in a prevalence of Enterobacteriaceae
(Escherichia spp., Enterobacter spp., Klebsiella spp., Proteus spp.), Lachnospiraceae, and Ruminococcaceae,
and a reduction of Bifidobacteriaceae (Bifidobacterium spp.), Lactobacillaceae (Lactobacillus spp.),
Bacteroidaceae, and Prevotellaceae [59]. In CKD there is an increase in bacteria with proteolytic
activity, responsible for the production of uremic toxins (such as indoles, phenols, and trimethylamine),
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amines with biological activity (such as histamine, tyramine) and hydrogen compounds (such as
hydrogen sulfide, methane). Additionally, there is a decrease in bacteria with saccharolytic activity
responsible for the production of short chain fatty acids (SCFAs), water, CO2, and alcohols [60].
SCFAs introduced in the organism mainly through a fiber rich diet, perform various functions
involved in the maintenance of eubiosis (a condition of equilibrium, characterized by a positive gut
microbiota status) including tropism, being the main source of energy for the colonocytes, and the
modulation of the gut immune system [61]. Moreover, SCFAs regulate the immunomodulatory
activities of intestinal macrophages, the most abundant immune cell type in the lamina propria.
Previous studies [62] demonstrated how patients affected by intestinal chronic inflammatory
diseases cause a reduction of bacteria able to produce SCFAs. The oral administration of SCAFs
(n-butyrate) in rats highlighted their modulatory action in the immune response of macrophages in the
lamina propria. Through the inhibition of histone deacetylase, an enzyme involved in the production
of inflammatory cytokines such interleukin (IL) 6, and IL-12 suggests that the reduction of saccharolytic
bacteria, and consequently of SCFAs, could exacerbate the chronic inflammatory status present in
patients with CKD [63,64].
Amongst the different uremic toxins produced by proteolytic bacteria in dysbiosis of CKD patients,
the most studied are: trimethylamine-N-oxide (TMAO), indoxyl sulfate (IS), and p-cresyl sulphate (PCS).
TMAO derives from the metabolism of choline and carnitine in the intestinal tract and the following
hepatic oxidation. Its increment is inversely correlated to a reduction of estimated glomerular filtration
rate (e-GFR) [65–67]. Studies conducted on animal models and on humans [68,69] have demonstrated
that TMAO increases CV risk and promotes atherosclerosis. However, the specific mechanism of action
in which TMAO induces atherosclerosis has yet to be elucidated. It is hypothesized that TMAO acts as
a uremic toxin deriving from the intestine, which contributes to the chronic inflammatory state typical
of chronic renal disease. In patients with moderate-severe CKD, TMAO represents an independent
predictor of CV mortality [68,69], and its levels are directly proportional to inflammatory biomarkers
(such as high-sensitivity C-reactive protein (hs-CRP) and IL-6). Moreover, it is worth highlighting that
TMAO levels tend to reduce and normalize [67] in patients who have undergone a renal transplant.
Sun et al. [70] observed on murine models that TMAO appears to be responsible for kidney
interstitial tubular fibrosis and renal dysfunction. Moreover, enhanced TMAO levels are present in the
high-fat diet (HFD) induced obese mouse model. The authors also highlighted that in the HFD mouse,
renal interstitial fibrosis, and phosphorylation of SMAD3 (mothers against decapentaplegic homolog 3,
acts as a regulator of cell proliferation and differentiation, its phosphorylation plays a key role in renal
fibrosis) are significantly increased with respects to the values observed in mice fed a low-fat diet (LFD).
SMAD3 is a member of the SMAD protein family. In HFD mouse, the authors also observed a significant
increase in the levels of biomarkers of kidney dysfunction, oxidative stress, and proinflammatory
cytokines compared to LFD mice, specifically: kidney injury molecule-1 (KIM-1) and plasma cystatin
C (CysC), nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-4, tumor necrosis factor-α
(TNF-α), and IL-1 β. The confirmation of TMAO’s detrimental role in renal pathology was proven by
concomitant treatment with the trimethylamine inhibitor 3,3-dimethyl-1-butanol (DMB). DMB reduced
TMAO plasma concentration, and prevented the morphological and molecular changes, which were
highlighted in HFD mice.
IS derives from the metabolism of tryptophan by bacterial tryptophanase and subsequent
conjugation with a sulfate group in the liver. This uremic toxin may be related to oxidative stress
elicitation and to the production of pro-inflammatory cytokines [71], which in turn lead to the
creation of reactive oxygen species (ROS), that play a key role in the progression of CKD and in
the onset of its complications. The administration of IS in uremic rats showed that the overload
of this protein metabolite on residual nephrons is involved in the enhancement of bioactivity of
transforming growth factor (TGF) β-1 in the kidneys. In turn, the increase of TGF β-1 increases the
renal expression of metallopeptidase inhibitor 1 (TIMP1) and pro-alpha 1 collagen, leading to the
worsening of glomerular sclerosis and the decline of renal function [72]. IS can be considered as
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a powerful predictor of overall mortality, and CV events [73], having an indirect relationship with
renal function and a direct relationship with aortic calcification and pulse wave velocity (a marker of
arterial stiffness) in CKD patients.
PCS derives from intestinal proteolytic fermentation of tyrosine and phenylalanine, and from the
following conjugation with a sulfate group in the liver. Administration of PCS caused significant renal
tubular damage in 3/4 nephrectomized rats, by enhancing oxidative stress [74]. The renal toxicity of
PCS seems to be caused by its intracellular accumulation, leading to both amplified NADPH oxidase
activity and ROS production, which, in turn, triggers the production of inflammatory cytokines and
TGFβ-1 secretion involved in renal fibrosis. This mechanism is similar to that for the renal toxicity
of IS. Both PCS and IS plasma levels are related to an increased risk of CV events and death in HD
patients [75].
Mounting evidence from these studies [76] shows that dysbiotic gut microbiota, characterized by
uremic toxins (such as TMAO, IS, and PCS) produced by proteolytic bacteria, should be considered
one of the pathogenic factors associated with a greater risk of kidney disease progression.
Some food components may have a direct toxic action, for example, phosphates and oxalates
become toxic when they accumulate during CKD. While other nutrients can be processed by the gut
microbiota, directly producing uremic toxins or their precursors that are, in turn, metabolized into
toxins. Higher intake of these nutrients may change the gut microbiota composition, increasing the
number of bacteria that process them and causing uremic toxin production [76].
Circulating levels of nutrient-derived uremic toxins are related to an increased risk of CKD
progression. These findings pave the way for future therapeutic approaches, particularly through the
modification of the intestinal gut microbiota composition, in order to impact directly on the production
of uremic toxins [77].
4. Microbiota and Diabetes Mellitus
DM is a metabolic disorder characterized by chronic hyperglycemia, which causes organ
damage in the retina, kidney, nervous system and CV system [78]. Diabetic patients are in a state
of low-grade chronic inflammation [79–81]. Over the years, evidence has been collected on the
involvement of dysbiosis in the occurrence of insulin resistance and in the development of a chronic
inflammatory process.
An interesting study [82] relates the alteration and increment in bacterial lipopolysaccharide (LPS)
plasma concentration with dietary modification. Normally LPS plasma levels vary in a consistent
manner with the circadian cycle, however, it was shown that the administration of an HFD could
cause a disruptive effect on this relationship. After only four weeks, an increase in circulating LPS was
demonstrated. The authors have termed this condition “metabolic endotoxemia” and have observed
that it is involved in driving the expression of inflammatory cytokines like TNF-α, IL-1, and IL-6.
Moreover, the role of LPS and metabolic endotoxemia in insulin resistance has been explored by
inducing a suppressive mutation of CD14, an important LPS receptor. The CD14 suppressed mice
showed hypersensitivity to insulin, leading to the inference that the interaction between LPS and its
receptor regulates insulin sensitivity.
It has been; therefore, hypothesized that metabolic endotoxemia regulates both the glyco-metabolic
state and chronic inflammation [83]. Consequently, reducing plasma LPS concentration could be
a potential therapeutic weapon for the glyco-metabolic control in the DM patients [79].
Combined administration of norfloxacin and ampicillin in ob/ob mice (genetically modified
obese mouse model, lacking the satiety hormone “leptin”) [84], greatly reduced the number of
anaerobic and aerobic bacteria in the cecum. After two weeks of antibiotic combination, the authors
observed a reduction in fasting glycemia and oral glucose tolerance of ob/ob diet-induced obese and
insulin-resistant mice. Moreover, a decrease of liver triglycerides (TG), plasma LPS and an increase
adiponectin was observed [85]. Therefore, the modulation of the microbiota through antibiotics could
ameliorate glucose tolerance and the inflammatory process.
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Interestingly, some bacteria can have a protective role against the onset of metabolic diseases.
For example, the abundance of A. muciniphila is decreased in obese and type 2 diabetic mice, and is
normalized by prebiotic feeding with oligofructose [86].
A. muciniphila treatment reverted HFD induced metabolic disorders, as well as fat-mass gain,
metabolic endotoxemia (lowering serum LPS levels and mRNA expression of CD11c, biomarker of
adipose tissue differentiation), adipose tissue inflammation, and insulin resistance in diet-induced
obese mice. In addition, A. muciniphila administration re-established gut barrier function and enhanced
gut endocannabinoid content (acylglycerols), which control inflammation and glucose homeostasis [43].
As demonstrated in animals, LPS levels are increased in humans affected by type 2 diabetes mellitus
(T2DM) and obesity. LPS activates toll-like receptors (TLRs), which in turn induce inflammation
and enhance the production of potentially diabetogenic pro-inflammatory cytokines produced by
the adipose tissue, such as IL-6 and TNF-α. Furthermore, the administration of antidiabetic therapy
(rosiglitazone) is responsible for the decline of the LPS and fasting serum insulin levels in previously
untreated T2DM patients [87]. An interesting study has demonstrated that levels of bacteremia are
correlated with the development of T2DM; in fact, the 16S rDNA concentration (a specific bacterial
marker) was higher in those subjects destined to have diabetes in comparison to those who do not
have a predisposition to develop the disease [88]. 16s rDNA ribosomal sequencing is a universal,
rapid and accurate technology which is useful in order to identify bacteria present in examined samples.
Particularly, it is advantageous in cases of uncultivable, slow growing, rare, or unusual bacteria. It may
constitute a diagnostic technique in case of infections with a negative culture [89]. Zhang et al. [90]
sequenced the microbial 16S rRNA genes of fecal samples of three different subgroups divided
according to their glucose intolerance status (normal tolerance, prediabetes and T2DM individuals).
This study showed that every progressive stage of the development of diabetes is related to a specific
change in the composition of the gut microbiota. Glucose tolerance decreases along with the presence of
butyrate producing bacteria such as A. muciniphila and Fecalibacterium prausnitzii and is also associated
with a decrease of Verrucomicrobiae. The abundance of Streptococcus continued to decrease together
with the glucose tolerance increase. These results suggest that the composition of gut microbiota could
be potential marker for a high risk of DM, and the conservation of gut microbiota homeostasis in the
prediabetes stage may be a strategy to delay the development of the pathology [90].
Qin et al. [91] developed a protocol termed “metagenome-wide association study” (MGWAS)
based on the sequencing of the gut microbial DNA from 345 Chinese individuals, to compare the
genetic content of the fecal microbiota between healthy and diabetic subjects. They identified and
validated about 60,000 T2DM associated gene-sequence, showing that patients with T2DM were
identifiable by a moderate grade of gut dysbiosis, more specifically by a reduction in the abundance of
some butyrate-producing bacteria and a raise in opportunistic pathogens, an improvement of other
microbial activities inducing sulfate reduction and oxidative stress resistance. These biomarkers could
be useful for the classification of T2DM patients.
Subsequently, Karlsson et al. [92] developed a mathematical model to characterize the fecal
metagenome of a cohort of European women with normal, impaired, and diabetic glucose control.
Then they selected a possible metagenomic profile to accurately characterize individuals with T2DM.
Interestingly, they applied their model to the previously cited Chinese cohort [91] and showed that the
metagenomic markers for T2DM are different in the two cohorts examined (European and Chinese),
suggesting that metagenomic predictive tools for T2DM should be defined according to age and place
of origin of the individuals.
5. Microbiota and Arterial Hypertension
HTN is one of the most prevalent CV diseases worldwide and scientific evidence from both
human and animal studies suggest that a number of factors (such as dietary habits, physical activity,
pregnancy, and use of antibiotics), are closely related to HTN onset through their effect on the gut
microbiota [93].
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Tao Yang et al. [94] conducted a multi-step study on fecal samples containing bacterial DNA found
in a spontaneously hypertensive rat (SHR) model, comparing it to that of Wistar Kyoto normotensive
rats. Subsequently, they compared fecal samples from a cohort of patients with essential hypertension
(EH), to a healthy subject control group. Finally, they analyzed the samples from chronic angiotensin II
infusion rats (model in which hypertension is induced pharmaceutically) comparing them to the SHR.
The results showed that, in the spontaneously hypertensive rats, a significant reduction in microbial
abundance, diversity, and uniformity, together with an increased F/B ratio and a diminished abundance
of acetate and butyrate producing bacteria were observed. The alterations observed in the SHR were
comparable to the changes found in the chronic angiotensin II infusion rats, confirming that dysbiosis
was independent from the mode of HTN insurgence. The EH patient cohort presented a similar
dysbiotic pattern to the hypertensive rats. Successively, in order to evaluate if the eventual restoration
of the F/B ratio could induce a positive effect on the blood pressure (BP), the authors administered
a minocycline-based therapy to the chronic angiotensin II infusion rats. Such procedure highlighted
a slight improvement of BP values as a consequence of the restored F/B.
A study by Adnan et al. [95] showed that the transplantation of SHR microbiota in normotensive
rats induced an increase of systolic BP and dysbiosis by increasing the F/B ratio, confirming that the
F/B ratio alteration is associated to the surfacing of systemic pathologies such as HTN.
The sequencing of 16S rRNA genes from fecal samples of Dahl salt-sensitive rats (S) [96], a genetic
model of HTN, and Dahl salt-resistant rats (R), a genetic model of normotension, showed significant
differences between S and R groups in gut microbiota composition. In particular, the authors observed
that Bacteroidetes, particularly the S24-7 family, and the Veillonellaceae family of the Firmicutes
phylum, were significantly higher in the S rats respect to the R rats. This confirms the pivotal role
played by the F/B alteration in the development and maintenance of EH.
Pluznick et al. [97] reported that SCFA (specifically propionate) administration in mice produces
hypotension because of the disruption of the olfactory receptor 78 (Olfr78, a receptor expressed in
the juxtaglomerular afferent arteriole that mediates renin secretion in response to the production of
SCFA) and the expression of G protein receptor 41 (Gpr41, a regulator of the smooth muscle cells of
small resistance vessels). In addition, antibiotic therapy in the Olfr78 knockout mice reduces the gut
microbiota biomass and increases BP, suggesting that SCFAs produced by the gut microbiota might
modulate the BP via Olfr78 and Gpr41 activity. Therefore, accumulating evidence from these studies
suggests that changes in the composition of gut microbiota plays a fundamental role in the induction
and furthering the progression of HTN.
Research conducted in China [98] examined the composition and function of gut microbiota by 16s
metagenomic sequencing in 196 participants, grouped in healthy control, pre-HTN (pHTN), and HTN
patients. Compared to the healthy controls, the study confirmed a dramatically decreased microbial
richness and diversity in both pHTN and HTN groups. Moreover, Prevotella dominated the gut
enterotype of pHTN and HTN groups, which showed distinct metagenomic composition characterized
by reduced bacterial species associated with a healthy phenotype, and a concomitant overgrowth of
bacteria such as Klebsiella.
The microbiome characteristic in pHTN group and HTN group were similar. In addition, the fecal
transplantation from hypertensive human donors to germ-free (GF) mice caused an elevation in BP,
suggesting that HTN could be transferrable through the gut microbiota.
Overall, gut microbiota can contribute to the pathogenesis of HTN, and the first signs of dysbiosis
can be found in the pHTN phase, suggesting that early intervention in this stage could be a future
strategy to control this pathology.
Nowadays, the gut microbiota modulation appears as a useful tool in the prevention and care of
dysbiosis associated with CKD, DM, and HTN. It may be modulated through the administration of
antibiotics, prebiotics, and probiotics, or by fecal transplantation. The following sections will focus on
the interest of probiotic, prebiotic, and synbiotic approaches in the management of these diseases.
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6. Probiotics
The Food Agricultural Organization/World Health Organization (FAO/WHO) has defined
probiotics as “live microorganisms which, when administered in adequate amounts, confer a health
benefit to the host” in agreement with the International Scientific Association for Probiotics and
Prebiotics (ISAPP) [99].
Probiotics are able to change the microorganism population of the gut microbiota and control
the correct functioning of this ecosystem. The potential of probiotic strains has recently motivated
researchers to study the production of foods with probiotic activity.
The importance of probiotic foods, such as yogurt and other fermented milks, was already
recognized since the beginning of the 20th century (Table 1).
Table 1. Probiotics effects on CKD, DM and HTN.






22 HD patients RDBPC
Reduction in:
WBC count p < 0.057
CRP serum level p < 0.071




2014 30 stage III–IV CKDpatients RCT Decrease in the serum urea level p = 0.031
Miraghajani M
[102] 2017
48 DKD patients RCT
Decrease in:
Oxidized GSH p = 0.03
Increase in:
GSH p = 0.01
GSH peroxidase p = 0.001
GSH reductase p = 0.02
Borges NA
[103] 2018
46 HD patients RDBPC
Increase in:
Serum urea p = 0.2
Potassium p = 0.2
IS p = 0.2
Decrease in:
Fecal pH p = 0.1





Improvement of glycemic and
lipid profile (blood glucose,
HbA1c, glucose intolerance,
plasma insulin, liver glycogen,
PTC, TG, LDL, VLDL HDL,
and FFA)
p < 0.05





Improvement of glycemic and
lipid profile (blood glucose,
HbA1c, glucose intolerance,
plasma insulin, liver glycogen,
PTC, TAG, LDL, VLDL, and FFA)
and oxidative stress markers
(GSH, TBARS)
p < 0.05
Khalili L [106] 2019 40 T2DM patients RCT
Increase in SIRT1 p = 0.04
Decrease in:
Fet1 p = 0.023
FBG p = 0.013
HbA1c p = 0.07
Insulin p = 0.028
HOMA.IR p = 0.007
Firouzi S [107] 2015 136 T2DM patients RDBPC Decrease in the serum urea level p < 0.05
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Table 1. Cont.











FBG p = 0.034
Fasting plasma insulin p = 0.001
HOMA.IR p = 0.001




RSNA p = 0.0005
BP p = 0.0005
Increase in:






Systolic BP p < 0.01
Increase in the relaxation induced
by acetylcholine
Increase in:
eNOS activity p < 0.05
Phosphorylation of eNOS
and cardiac and renal
hypertrophy
p < 0.05
Ahrén IL [111] 2015 54 inducedhypertensive rats RCT Decrease in BP p < 0.05
Tuomilehto J
[112] 2004




Systolic BP p = 0.0668






Systolic BP p = 0.01
Diastolic BP p = 0.48
Aoyagi Y [114] 2017 352 normotensivepatients RCT
Decrease of the risk of
developing HTN p = 0.037
BP, blood pressure; CKD, chronic kidney disease; CRP, C-reactive protein; DKD, diabetic kidney disease; eNOS,
nitric oxide synthase; FBG, fasting blood glucose; FetA: fetuin A; FFA: free fatty acid; GSH, glutathione; GVNA,
gastric vagal nerve activity; HbA1c, glycated hemoglobin; HD, hemodialysis; HDL: high-density lipoprotein;
HOMA, homeostatic model assessment; HOMA-IR, homeostatic model assessment for insulin resistance; HTN,
arterial hypertension; IG, indoxyl glucuronide; IS, indoxyl sulfate; LDL, low-density lipoprotein-cholesterol; PTC,
plasma total cholesterol; RCT, randomized control trial; RDBPC, randomized, double-blind, placebo-controlled;
RSNA, renal sympathetic nerve activity; SIRT1: Sirtuin1; T2DM, diabetes mellitus type 2; TAG, triacylglycerol;
TBARS: thiobarbituric acid reactive species; TG, triglycerides; VLDL, very-low-density lipoprotein-cholesterol;
WBC, white blood cell.
In fact, in 1907, Nobel Laureate Elie Metchnikoffn [115] suggested the value of probiotics,
observing that Bulgarian peasants lived longer lives because of their yogurt consumption.
Most probiotic products today are developed with Bifidobacteria, Lactobacilli, and other
lactic acid producing bacteria, such as Lactococci and Streptococci. Other probiotic strains that
could induce beneficial effects on health status include the bacterial genera Bacillus, Escherichia,
and Propionibacterium and some other yeast genera, mainly Saccharomyces. Probiotics are
generally considered safe for human health with reduced adverse effects [116]. Several species
and strains of Lactobacilli, including Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosus,
and Lactobacillus helveticus, have been extensively studied in the prevention of NCDs. We are going to
discuss the role of probiotics in CKD, DM, and HTN.
6.1. Probiotics and CKD
Several studies have been conducted in order to quantify the efficacy of probiotics. Not only in
relation to their capacity to decrease the concentration of uremic toxins and to better renal function
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indices, but also in the role they play in order to reduce the systemic inflammatory status present in
CKD patients. However, these studies have elucidated some discrepancies, which will be discussed in
the following paragraph.
Wang et al. [117] showed that supplementation of probiotics containing Bifidobacterium bifidum
A218, Bifidobacterium catenulatum A302, Bifidobacterium longum A101, and Lactobacillus plantarum
A87 in peritoneal dialysis (PD) patients significantly reduced the serum levels of endotoxins and
pro-inflammatory cytokines (TNF-α, IL-6 and IL-5), together with increasing the serum levels of
anti-inflammatory cytokine (IL-10), and preserving residual renal function. It has been demonstrated
that inflammatory cytokines (particularly IL-6 and TNF-α) are increased in dialysis patients and are
correlated to increased CV events and overall mortality [118,119]; whilst endotoxins are both cause and
markers of CKD related inflammation [120]. For such reason probiotics could be a valid instrument for
improving CKD related prognosis.
The beneficial effect of probiotics on intestinal health has been known for centuries. For this
reason, they have been studied in the management of end stage renal disease both in animal models
and humans. In recent years, [121] these effects have been related to the progression of CKD,
highlighting their anti-inflammatory, re-equilibrating action to restore eubiosis, and their antioxidant
properties, reducing the ROS production by the gut microbiota.
Animal studies [122] have demonstrated that the gut microbiota can influence the concentration
of uremic toxins, and the administration of probiotic “cocktails” can increase life expectancy in uremic
rats, by reducing levels of urea nitrogen. Similar formulations of probiotics have been administered to
CKD patients, stage III–IV, and according to the Kidney-Disease Outcomes Quality Initiative (K-DOQI)
guidelines [100], they induced a statistically significant reduction in urea nitrogen levels [123].
A randomized, double-blind, placebo-controlled trial of strain-specific probiotic formulation
with Streptococcus thermophilus (KB19), L. acidophilus (KB27), and B. longum (KB31) (Renadyl) [124]
in HD patients has highlighted a series of beneficial effects elicited by Renadyl, as shown in Table 1.
Most notable is Renadyl’s action on IS (also confirmed in animal models), because it has been shown
how IS reduces erythropoietin (EPO) production in vitro [125,126]. Therefore, this uremic toxic has been
proposed to be involved in the insurgence of anemia during CKD by inhibiting the hypoxia inducible
factor (HIF), which in turn is responsible for the activation of EPO [127]. It is postulated that particular
probiotic formulations (such as Renadyl) could be useful to contrast normochromic and normocytic
anemia typical of CKD. This could represent a new combinatorial therapy, which would allow the
reduction of weekly EPO dosage eliciting both therapeutic and pharmaco-economic advantages.
Moreover, in this study, no statistically significant changes were observed in measures of Kidney
Disease Quality of Life (KDQOL) [101,124]. This data demonstrated that Renadyl administration in
uremic patients is well tolerated and safe [128].
Miranda Alatriste et al. [102,129] observed that administration of substantial quantity of probiotic
agents (L. casei shirota 8 × 109 UFC vs. 16 × 109) leads to a greater decrease (>10%) in blood urea levels
in patients with stages III–IV of CKD according to K-DOQI guidelines [100]. This study demonstrates
that not only the probiotic typology, but also the administered quantity influences the efficacy of the
treatment. Ulterior RCTs are necessary to investigate the adequate dosage for nephropathic patients.
Miraghajani et al. [130] researched the effect of probiotic soy milk consumption on oxidative stress
factors among type 2 DKD. DKD pathogenesis is conditioned by a plethora of factors, one of which is the
oxido-reductive equilibrium [131]. It has been demonstrated that in T2DM patients there is a significant
reduction in the plasmatic ratio between GSH/GSSH [132] and ROS hyper-production (both factors are
involved in producing renal damage [133] and in the insurgence of precocious complications related to
diabetes). In fact, various studies convene that increased oxidative stress in DM patients is closely
correlated to the precocious insurgence of complications [103,134]. The results, as shown in Table 1,
suggests that soy milk supplementation may help in the achievement of an improved antioxidant
status in DKD patients, reducing risk factors correlated to its development.
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A randomized, double-blind, placebo-controlled trial on HD patients investigated the effects of
probiotic supplementation for a three-month period (S. thermophilus, L. acidophilus, and B. longum),
this study highlighted discrepant result regarding the uremic profile and the gut microbiota of these
patients. On one hand, there was a reduction in the fecal pH of the HD patients, a positive sign indicating
an improvement in the gut microbiota flora composition. In fact, according to some studies probiotics
increase bacterial production of organic acids and reduce pH in the colic lumen, thus inhibiting
pathogenic growth [135,136]. On the other hand; however, rather than achieving normalization of
uremic toxins, a significant increase in serum urea, potassium, and IS was observed. The trial showed
that probiotic intervention did not seem to induce a positive effect on the inflammatory status and
biochemical parameters in HD patients, cautioning health professionals on the administration of
probiotics in these subjects.
In order to elucidate the real benefice induced by probiotics on uremic patients, given that the
studies conducted to this date are all on limited samples and produced discording results, it would be
necessary to carry out RCTs on a larger population and the effects should be availed by a lengthier
follow-up period.
6.2. Probiotics and Diabetes
There is increasing evidence that oral administration of probiotics could reduce serum glucose
levels and ameliorate the metabolic and inflammatory status of DM patients [104,137].
The consumption of skim milk and dahi, a traditional Indian fermented milk (containing
Lactobacillus lactis ssp. lactis, L. lactis ssp. cremoris, L. lactis ssp. diacetylactis, and Lactobacillus citrovorum),
was shown to ameliorate glycemic and lipid profile in high fructose fed (HFF) rats, as reported in
Table 1 [105,106]. The authors hypothesized that some of the results could depend on the capacity
of fermented to modify gut bacterial content. There is an increase in bacteria that produce SCFAs,
which reduce plasmatic cholesterol. Moreover, there is an increase in bacteria involved in the
de-conjugation of biliary acids. Biliary acids in this form cannot be reabsorbed by the intestinal mucosa,
so their de novo synthesis increases, with consequent cholesterol consumption leading to its secondary
reduction. It would be useful to test the effects of this probiotic on the lipid and glycemic profile on
T2DM patients in order to assert its therapeutic potential.
A second study by same authors [107], investigated the effect of L. acidophilus and L. casei containing
dahi on HFF rats. The authors propose that this kind of probiotic supplementation has a truly beneficial
effect on the specimens. The study compared glycemic and lipid profiles of the HFF rats supplemented
with dahi to an HFF control group after eight weeks, confirming the positive effect on such profiles,
and highlighting its antioxidant effect (Table 1). In such regards, the antioxidant action of probiotics
at the hepatic and pancreatic level has been proposed, as it was shown that dahi supplementation
inhibited thiobarbituric acid reactive species elevation as well as decreasing reduced GSH. In conclusion,
the administration of probiotics contained in dahi has induced, in animal models, multiple beneficial
effects improving not only the glycemic profile, but also the lipid one and reducing oxidative stress.
A randomized controlled trial on diabetic patients [138] demonstrated that the administration of
L. casei decreased parameters for related with glycemic metabolism (Table 1). Moreover, this study
revealed a new role for L. casei supplementation in the glucose homeostasis. This probiotic significantly
increased sirtuin1 (SIRT1) plasmatic concentration NAD-dependent deacetylase, which participates in
the improvement of insulin sensitivity, its increment has a positive effect on the glycemic profile of the
patients. At the same time, a decrease fetuin A (FetA) plasma concentration was observed. FetA is
a serum protein, which inhibits the insulin receptor autophosphorylation and decreases efficiency
of insulin signaling. The compounded increment of SIRT1 and reduction of FetA could significantly
improve the glycemic status of DM patients. Therefore, the administration of this probiotics could be
used as an association therapy finalized to ameliorate the glyco-metabolic status of patients.
A study by Firouzi et al. [139] demonstrated that administration of probiotics in patients with
T2DM decreases urea plasma levels but does not significantly change other renal function parameters
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(creatinine and eGFR) and electrolytes (plasma levels of sodium, potassium), suggesting the necessity to
perform further studies, regarding the role of probiotics in DM and its associated complications. It was
hypothesized that uremic subjects, being characterized by dysbiosis, presented higher levels of aerobic
bacteria (Escherichia coli) and lower levels of anaerobic bacteria (Lactobacillus and Bifidobacterium).
Increased concentration of E. coli induced higher urea production, and an increase of intestinal pH.
Therefore, the administration of Lactobacillus and Bifidobacterium could induce a pH reduction,
and prevent the proliferation of aerobic bacteria [108,140].
Kijmanawat A et al. [141] showed that four weeks of probiotic supplement administration,
containing B. bifidum and L. acidophilus, in women with diet-controlled gestational DM, in the late
second and early third trimester, ameliorate the glycemic profile (Table 1). This evidence suggests that
probiotic supplements may be considered as an adjunct treatment for glycemic control in gestational
diabetes, protective for both the mother and the newborn as the intrauterine environment can influence
the long-term metabolic health of the offspring.
6.3. Probiotics and Hypertension
The beneficial effects of probiotics on BP have been reviewed in recent years [109,142]. The literature
states that some lactic acid bacteria, such as Lactobacillus johnsonii La1 (LJLa1), have a hypotensive
action in rats [143]. A Japanese group [143] proposed that the hypotensive action of LJLa1 itself or
its metabolites may be due to the regulation of the autonomic nervous system. In order to test this,
LJLa1 intraduodenal injections were administered to urethane-anaesthetized rats. It was reported
that these injections reduced renal sympathetic nerve activity (RSNA), reduced BP, and increased
gastric vagal nerve activity (GVNA). Such study highlights how probiotics, in this case L. johnsonii
La1, can have an antihypertensive effect through the modulation of the microbiota, reduction of
pathogenic species, and a direct effect on the systems involved in regulating of arterial pressure.
In recent years, the correlation between HTN and RSNA hyperactivation has received considerable
attention [144]. Some experimental trials have been pursued in order to evaluate the efficacy of selective
sympathectomy in HTN resistant to pharmacotherapy [110,145]. The use of probiotics; however,
could represent a non-invasive, side effect free, preventative therapy.
Gómez-Guzmán et al. [146] produced a study, which claims to have demonstrated for the first
time the positive effect of long-term oral supplementation of probiotics to alter the HTN profile in rats,
by improving endothelial function, decreasing vascular inflammation and oxidative stress, and by
reducing BP. Rats were either administered Lactobacillus fermentum CECT5716 (LC40) or Lactobacillus
coryniformis CECT5711 (K8) plus Lactobacillus gasseri CECT5714 (LC9). Both formulae managed to restore
the impaired capacity of the aortic endothelium to relax in response to acetylcholine, a vasodilator
with NO-agonist activity. This probiotic treatment also acts through the restoration of eubiosis and
bacterial ratio, inducing a change in the cecum microbiota, with higher counts of the Lactobacillus
spp. cluster, and lower counts of Bacteriodes spp. and Clostridium spp. Moreover, when administered
to spontaneously hypertensive rats (SHR), they decreased both NADPH oxidase activity, leading to
a reduction of the aortic superoxide production, and TLR4. The latter is a factor of the innate immune
system involved in system inflammation; in recent years, its putative role in the pathogenesis of HTN
has emerged. Animal studies have shown how angiotensin II acts through the activation of TLR4
pathways; however, the precise mechanism has yet to be elucidated [111,147]. This study shows that
probiotics represent a possible therapeutic tool for the treatment of genetic HTN.
Ahrén et al. [148] demonstrated that the supplementation of L. plantarum DSM 15,313 fermented
blueberries significantly reduced systolic and diastolic BP, by controlling the NO dependent pathway
in a hypertensive rat model treated with nitro-L-arginine methylester (L-NAME—a hypertensive drug).
The beneficial effect of L. plantarum is enhanced by products the fermentation of blueberries, which are
phenolic acids (hydrox-yphenyllactic acid, 3,4-dixydroxyphenyl-propionic acid and phenyllactic acid),
which hold anti-hypertensive properties [112].
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Fermented milk can be considered as functional drink acting against HTN. In recent years
the capacity of probiotics to reduce BP was related to the release of bioactive peptides during
the fermentation process, such as the angiotensin-converting enzyme (ACE) inhibitory peptides,
having a hypotensive function similar to that of ACE-inhibitor drugs. Two tripeptides that inhibit
ACE, isoleucyl–prolyl–proline (Ile-Pro-Pro) and valyl–prolyl–proline (Val-Pro-Pro), have been isolated
from sour milk fermented with L. helveticus and Saccharomyces cerevisiae bacteria [113].
A study of Tuomilheto et al. [149] demonstrated that the administration of this product,
containing the ACE inhibitory peptides in patients with mild hypertension, could have a slight
BP lowering effect.
A randomized, double-blinded placebo-controlled parallel group study [114] on hypertensive
patients confirmed that administration of L. helveticus LBK-16H fermented milk containing bioactive
peptides, consumed on a daily basis, had a BP lowering effect. Particularly, systolic pressure resulted
reduced by −7.6 mmHg. This information is significant, as some controlled trials have demonstrated
how anti-hypertensive pharmaceuticals reduce stroke risk by 1/6 with a systolic arterial pressure
reduction of 5 mmHg [150].
These two studies show how probiotics (in a similar way to pharmaceuticals) act on some of the
systems involved in HTN pathogenesis. For such reason, they should be considered as a possible
therapeutic tool for such pathology.
Aoyagi et al. [151] have highlighted that the risk of developing HTN is significantly lower in
elderly subject who take fermented milk products containing L. casei strain Shirota (LcS) at least three
times per week. L. casei owes its anti-hypertensive properties to its polysaccharide component
(SG1–polysaccharide–glycopeptide complex), which increases prostaglandin I2 biosynthesis,
and reduces peripheral vascular resistance [152]. The results of Aoyagi’s study indicated that
Lactobacilli could also have a protective action in the development of hypertension, as well as having
a BP lowering effect.
In conclusion, probiotic intervention may be a potentially effective approach in the co-treatment
of HTN through the restoration of the gut microbiota.
7. Prebiotics
Gibson and Roberfroid devised the prebiotic concept in 1995 [153], defining prebiotics as
“a non-digestible food ingredient that beneficially affects the host by selectively stimulating the
growth and/or activity of one or a limited number of bacteria in the colon, and thus improves host
health”. Although this original definition has been revised several times, the main features have been
maintained [154]. In 2008, FAO defined prebiotics as a “nonviable food component that confers a health
benefit on the host associated with modulation of the microbiota” [155].
Prebiotics are functional food components, found naturally either in plant-based foods or from
synthetic production through the enzymatic conversion of sugars. These food compounds are
usually carbohydrate structures or soluble dietary fibers, which are selectively metabolized by human
microbes [156].
Oligosaccharides like inulin-type fructans and galactooligosaccharides represent the best-known
fibers in class of functional fibers and their prebiotic effects have been explored. In particular, it has
been observed that these oligosaccharides are able to stimulate the growth of Bifidobacteria and to
a lesser extent of Lactobacilli [156].
The modulation of gut microbiota via the administration of prebiotics has been studied throughout
the years as a potential instrument against the development and worsening of various diseases,
including CKD, DM, and HTN (Table 2).
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Table 2. Prebiotics effects on CKD, DM and HTN.










in stool p < 0.01
Decrease in:
Urinary nitrogen excretion p < 0.01
Plasma urea p < 0.05






Serum total PCS p = 0.07
Serum free PCS p = 0.07






PCS generation rates p = 0.007
PCS serum concentrations p = 0.03





Serum free IS p = 0.04
Serum free PCS ns
Poesen R [161] 2016
40 CKD patients with






No significant decrease of
serum uremic toxins level or
24h urinary excretion
ns






tissue weight p < 0.05
Leptin sensitivity p < 0.05
Proglucagon mRNA
expression p < 0.05
Enteroendocrine
cell activity p < 0.05
Dehghan P [163] 2014 52 women with T2DM RCT
Decrease in:
BMI p < 0.05
FBG p < 0.05
Hb1Ac p < 0.05
IL-6 p < 0.05
TNF-α p < 0.05
LPS p < 0.05
Bodinham CL [164] 2014 17 T2DM patients RCT
Decrease in: p = 0.045
Postprandial glucose
concentrations
NEFA p = 0.04
Fasting GLP1 p = 0.049
Increase in:
Glucose uptake across the
forearm muscle p = 0.077
Postprandial GLP1 excursions p = 0.009
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75 T2DM patients RCT
Decrease in: p < 0.05
FBI p < 0.05
HOMA-IR p < 0.05
QUICKI p < 0.05
TNF-α p < 0.05
IL-6 p < 0.05
Endotoxin p < 0.05
MDA p < 0.05
Marques FZ [166] 2017 64 hypertensive mice RCT
Increase in:
Acetate-producing bacteria p = 0.0001
Bacteroides acidifaciens species
bacteria p = 0.0001
Decrease in:
F:B ratio p = 0.0001
Systolic BP p = 0.0002
Diastolic BP p = 0.0001
Glomerular fibrosis p = 0.0001
Tubulointerstitial fibrosis p = 0.008
Cardiac perivascular and
interstitial fibrosis p = 0.001
Left ventricular hypertrophy p < 0.05
Xiao S [167] 2014 123 obese patients Self-controlled
clinical trial
Decrease in:
Bifidobacteriaceae bacteria p = 0.05
Systolic BP p = 0.01
Diastolic BP p = 0.05
Body weight p = 0.01
BMI p = 0.01
FBI p = 0.01
FBG p = 0.01
HOMA-IR p = 0.01
HbA1c p = 0.01
TG p = 0.01
PTC p = 0.01
LDL p = 0.05
TNF-α p = 0.05
IL-6 p = 0.01
CRP p = 0.05
Increase in:
HDL p = 0.05
Rault- Nania MH
[168] 2008
40 high fructose-fed rats RCT
Prevention of:
BP elevation p = 0.028
Hypertriglyceridemia p = 0.036
Susceptibility to heart
peroxidation p = 0.0001
Hsu CN [169] 2018





BP p < 0.05
BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease; CRP, C-reactive protein; eGFR,
estimated glomerular filtration rate; F:B ratio, Firmicutes to Bacteroides ratio; FBG, fasting blood glucose; FBI,
fasting blood insulin; FFA: free fatty acid; GLP1, Glucagon-like peptide-1; HbA1c, glycated hemoglobin; HD,
hemodialysis; HDL: high-density lipoprotein; HOMA-IR, homeostatic model assessment for insulin resistance;
IG, indoxyl glucuronide; IL-6, interleukin-6; IS, indoxyl sulfate; LDL, low-density lipoprotein-cholesterol; LPS,
lipopolysaccharide; NEFA, non-esterified fatty acid; PCS, p-Cresyl sulfate; PTC, plasma total cholesterol; QUICKI,
quantitative insulin sensitivity check index; RCT, randomized control trial; RDBPC, randomized, double-blind,
placebo-controlled; T2DM, diabetes mellitus type 2; TG, triglycerides; TNF-α, tumor necrosis factor-α. VLDL,
very-low-density lipoprotein-cholesterol.
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7.1. Prebiotics and CKD
Prebiotics represent a valid therapeutic alternative in the modulation of the gut microbiota
composition, by reducing the producing of microbial-derived uremic toxins, such as TMAO, IS,
and PCS.
Most dietary approaches finalized to treat CKD and to achieve alleviation of symptoms are based
on daily protein consumption restriction [157,158,170,171].
Younes et al. study the role of fermentable carbohydrate supplementation as an alternative dietary
attempt, in order to lower urea plasma levels [172]. The administration of fermentable carbohydrate
significantly benefits the status of hematic toxicity present in the treated subjects, as reported in Table 2.
These results suggest that the use of prebiotics produces similar beneficial effects in chronic renal
failure as those obtained with a low-protein diet. Moreover, such supplementation induces an increase
in body weight (around 600 g in five weeks). Such result is of particular clinical relevance, as the use
of fermented carbohydrates in association with a targeted dietetic-nutritional intervention, is able
to reduce uremic toxin levels and contrast the insurgence of malnutrition (frequent comorbidity in
nephropathic patients). Therefore, it would be advisable to perform a study on a higher number of this
kind of patients in conservative therapy to confirm the efficacy of such combined intervention on the
disease progression and on bodily composition.
Ramos et al. [159] investigated the effect of administering prebiotic fructooligosaccharide (FOS) on
uremic toxins of CKD patients undergoing conservative therapy. The results showed a reduction of total
serum and free PCS whilst no changes in urinary PCS, serum IS, and indole 3-acetic acid (IAA) were
recorded. The latter is a uremic toxin responsible for endothelial dysfunction, triggering inflammation
and oxidative stress, and it could be considered as an independent predictor of mortality and CV
events in CKD patients. The observed clinical effect following FOS administration resulted dependent
on the glomerular filtrate and the dietetic fiber/protein ratio [160]. Validating the possible therapeutic
efficacy of FOS in nephropathic patients following conservative therapy.
Similar results have been found by Meijers et al. [173] in HD patients. Their study showed
that prebiotic oligofructose-enriched inulin significantly reduced PCS generation rates and serum
concentrations in these patients. In contrast, neither IS generation rates nor serum concentrations
changed significantly. PCS appears to be a risk factor for CV pathologies; therefore, its reduction would
elicit a protective effect in their insurgence. Such hypothesis is yet to be confirmed by RCTs.
A successive study by Sirich et al. [174] on HD patients has obtained only partially consistent
findings Meijers’s. The enrolled HD patients received supplements containing resistant starch (RS).
After six weeks of this supplementation, increasing the dietary fiber reduced the unbound, free plasma
level of IS. However, the decrease of PCS levels was slighter and did not reach significance. To fully
evaluate the effect elicited by probiotics on uremic toxin levels in HD patients, it would be necessary
to enroll more subjects and lengthen the probiotic administration time. In case the reduction of
uremic toxins was confirmed, the therapy would result useful in the detoxification of HD patients,
which would be advantageous for their quality of life and life expectancy; especially because, currently,
dialytic strategies are not completely effective in the removal of these toxins [161,162].
Poesen et al. [163] conducted a study in patients with eGFR between 15 and 45 mL/min/1.73
m2 treated with prebiotic arabinoxylan oligosaccharides (AXOS). No significant effect of AXOS on
serum uremic toxins level or 24 h urinary excretion such as PCS, p-cresyl glucuronide (PCG), IS,
and phenylacetylglutamine (PAG) was observed, but only a slight decrease in serum TMAO.
These studies have demonstrated how the reduction of the most notable uremic toxins of bacterial
origin is only partial. Different prebiotics are able to selectively reduce uremic toxins. In conclusion,
further studies are necessary to elucidate the effective therapeutic action of prebiotics in uremic patients
and their role in the reduction of the gut microbiota uremic toxins.
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7.2. Prebiotics and Diabetes
Both animal- and human-based studies have been conducted in order to comprehend the role of
prebiotics in the modulation of glycometabolism in DM.
Prebiotic supplementation with oligofructose in ob/ob mice decreased F/B ratio,
increasing Bacteroidetes prevalence [164]. This type of supplementation positively altered the
gut microbiota profile, shifting it towards a status of eubiosis (increase of Bifidobacteria). In addition,
prebiotics improved lipid and glycemic profiles (Table 2) and, moreover, increased the enteroendocrine
L-cell number (involved in the increment of colon weight and length) and ameliorated other parameters
(intestinal proglucagon mRNA expression and portal plasma glucagon-like peptide-1 level—GLP1,
an incretin that increases insulin release from the pancreas). Furthermore, oligofructose prebiotic
supplementation reduced adipose tissue mass, muscle lipid infiltration, oxidative stress (decreasing
NADPH oxidase), and inflammation status (reducing IL-1) [165]. This new evidence highlights the
potential role for prebiotics in gut microbiota modulation, and their ability to benefit the health of the
subject by improving the glyco-metabolic status.
A study by Dehghan [175] has demonstrated that the daily administration of oligofructose-enriched
inulin to T2DM women, significantly improved their BMI, insulin resistance, and inflammatory profile
(Table 2). This confirms that prebiotics may help in the modulation of inflammatory status as well as in
lowering glucose plasma levels in humans. However, this should be confirmed by ulterior studies,
monitoring anti-inflammatory effects by quantifying phlogoses indexes in T2DM patients.
Since the positive role played by RS supplementation in healthy individuals and those with
metabolic syndrome had already been elucidated, Bodinham et al. [166] set out to investigate its
potential beneficial role in T2DM. The study was carried out on a patient sample with well-managed
T2DM to whom RS was administered. The results (Table 2) suggest that the beneficial effects achieved
by RS supplementation related to meal glucose handling rely on a mechanism which upregulates
postprandial GLP1, without needing to modify patient lifestyle (alimentary habits and physical activity
levels) and the dose and type of hypoglycemic oral medication [176].
A study by Aliasgharzadeh et al. [167] examined the effects of resistant dextrin (a soluble
prebiotic fiber) on insulin resistance and inflammation in T2DM women, as reported in Table 2.
Particularly notable are the modifications in two insulin related distinct indexes, namely a decrease
in HOMA (homeostasis model assessment of insulin resistance, a computer-solved model used to
quantify insulin resistance and beta-cell function) and an increase in QUICKI (quantitative insulin
sensitivity check index, determining insulin sensitivity). These findings show that this type of dietary
fiber could act as a valuable supplementation for the control of T2DM, thanks to its anti-inflammatory
and insulin resistance modulatory properties. Furthermore, a reduction trend in the concentration
of FBG, HbA1c and hs-CRP was observed, even though it was not significant. Consequently, it was
deduced that resistant dextrin supplementation could reduce the inflammatory state and improve
insulin resistance in women with T2DM [168].
7.3. Prebiotic and Hypertension
Marques et al. [169] found that the consumption of a high fiber diet or acetate supplementation
changed the intestinal microbiota composition and incremented the abundance of acetate-producing
bacteria. Both fiber and acetate decrease gut dysbiosis, measured by F/B ratio, and increase the
prevalence of Bacteroides acidifaciens, a bacterium involved in the prevention of obesity and improvement
of insulin sensitivity in mice [177]. Both high-fiber diet and acetate supplementation, as shown in
Table 2, significantly decreased the BP, cardiac fibrosis, and left ventricular hypertrophy. In addition,
acetate markedly reduced renal fibrosis, sign of dysfunction, and CKD. Transcriptome analysis showed
that the protective role of high fiber and acetate was related to the down-regulation of cardiac and kidney
early growth response protein 1 (Egr1), a nuclear protein involved in cardiac hypertrophy, cardio-renal
fibrosis, and inflammation. Prebiotics can; therefore, intervene in NCDs, modulating gut microbiota
composition and acting directly on cellular systems involved in the evolution of such pathologies.
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Obese patients subjected to a diet based on whole grain, a traditional medicinal Chinese food,
and prebiotics (WTP diet), showed decreased BP and body weight, accompanied by increased insulin
sensitivity and improvement of the lipid profile (HDL, LDL, PTC, and TG) [178]. An amelioration
of dysbiosis was also evident, with a reduction of endotoxin-producing opportunistic pathogens
(Enterobacteriaceae and Desulfovibrionaceae) and an increase of gut barrier-protecting bacteria
(Bifidobacteriaceae). Moreover, an LPS reduction was observed together with proinflammatory
cytokines reduction, and anti-inflammatory adipokine increase (Table 2). In obese subjects, it may be
useful to flank a hypocaloric diet with prebiotics, capable of reducing weight, BP, improving the glycemic
and lipid profile, and limiting the low-grade chronic inflammatory status present in such condition.
Rault-Nania et al. [179] studied the effect of the supplementation with different inulin-type fructan
fractions towards common characteristics of the metabolic syndrome in fructose-fed rats (a typical
model of this syndrome). The most effective were the long-chain inulin and oligofructose-enriched
inulins. Their supplementation prevented fructose induced CV and kidney damage, as reported in
Table 2. All inulin-type fructan-containing diets prevented fructose-induced hypertriglyceridemia;
however, their mechanism of action is yet to be elucidated.
Hsu et al. [180] conducted an interesting study regarding the effect of a maternal high fructose diet
that induced HTN in the adult offspring. Maternal diet is proposed to have long-term developmental
programming hypertensive effects on the adult offspring’s phenotype. The supplementation therapy,
which involved either the administration of probiotic L. casei or prebiotic inulin, was shown to prevent
HTN in the adult offspring. Therefore, this kind of intervention during gestation can be considered as
a reprogramming strategy.
8. Synbiotics
In combination, prebiotics and probiotic bacteria create synbiotics, which can compound prebiotic
and probiotic benefits (Table 3).
The term synbiotic refers to the synergy present between prebiotic substrate and probiotic
organisms. The advantage of such combination lies in the increased survival of the probiotics while
passing through the upper intestinal tract, improving and stimulating subsequent implantation and
growth [181,182].
Eslamparast et al. [183] conducted a study on a group of subjects affected by metabolic syndrome.
They were administered either with synbiotic capsules (L. casei, L. rhamnosus, S. thermophilus,
Bifidobacterium breve, L. acidophilus, B. longum, and Lactobacillus bulgaricus, plus fructo-oligosaccharide)
and fructo-oligosaccharide, or with placebo capsules. The subjects were instructed to follow an energy
balanced diet and to perform physical activity. Results showed that the group treated with synbiotics
had significantly improved fasting blood glucose and insulin resistance compared to the placebo group,
signifying that synbiotics can have the important role of optimizing the effect of diet and exercise
regimens in subjects affected by metabolic syndrome.
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Table 3. Synbiotic effects on CKD, DM and HTN.








FBG p < 0.001
HOMA-IR p < 0.001
TG p < 0.001
PTC p < 0.01
Increase in:
HDL p < 0.001




Insulin plasma level p = 0.005
TAG plasma level p < 0.001
VLDL plasma level p < 0.001
HOMA-IR p = 0.003
HOMA for β cell
function p = 0.008
Increase in:
QUICKI p = 0.02
Pavan M [181] 2016
24 patients with CKD






A lower declining of
eGFR p < 0.001





Decrease of PCS level p < 0.05
Viramontes-Horner D






CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; FFA: free fatty
acid; HD, hemodialysis; HDL, high-density lipoprotein; HOMA, homeostatic model assessment; HOMA-IR,
homeostatic model assessment for insulin resistance; KTR, kidney transplant recipients; PCS, p-Cresyl sulfate; PTC,
plasma total cholesterol; QUICKI, quantitative insulin sensitivity check index; RDBPC, randomized, double-blind,
placebo-controlled; TAG, triacylglycerol TG, triglyceride; VLDL, very-low-density lipoprotein-cholesterol.
A. Ahmadi et al. [184] study determined the effects of symbiotic capsule containing L. acidophilus,
L. casei, and B. bifidum plus inulin in subjects affected by gestational diabetes. After six weeks of daily
capsule administration, serum insulin levels and HOMA function were decreased, while QUICKI
was increased. In addition, the serum TG and VLDL concentrations were significantly decreased.
The results indicate that synbiotic therapy could be a valuable approach in managing insulin and lipid
parameters in gestational diabetes.
Pavan et al. [185] examined the effects of prebiotic and probiotic supplementation plus low protein
diet in order to evaluate the effect of this combined approach on the progression of CKD. It was
observed that this kind of therapeutic treatment was able to decrease the decline in eGFR in stage
III–IV CKD patients, compared to the dietary restriction alone. The administration of synbiotics,
associated to a low-protein diet may therefore enhance the efficacy of the diet in order to slow down
CKD progression.
A study by Guida et al. [186] suggests that treatment with synbiotics (containing L. plantarum,
L. casei ssp. rhamnosus, L. gasseri, Bifiodbacterium infantis, B. longum, L. acidophilus, Lactobacillus salivarius,
Lactobacillus sporogenes, S. thermophilus, inulin, and tapioca-resistant starch), may be effective in lowering
plasma PCS concentrations in kidney transplant recipients (KTR). A pilot study was conducted on
36 KTR and showed that after 30 days of treatment plasma PCS decreased by 30%, compared to
baseline, in the synbiotic treated group, whilst no significant changes in renal function, glycemia,
plasma lipids, or albumin concentration were observed. Therefore, successive studies on a larger scale
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and with a longer follow up period are required in order to determine if such intervention also has
some cardioprotective roles.
Finally, synbiotic gel (L. acidophilus, B. lactis and inulin) administration for the control
of gastro-intestinal symptoms (GIS) and complications in HD patients has been explored.
After a two-month long treatment, there was a significant reduction in the frequency and severity
of symptoms such as vomit, heartburn, and stomachache; evaluated thanks to a self-administered
questionnaire. The study concluded that synbiotic gel treatment is a safe yet simple strategy to control
common GIS during HD [187].
9. Postbiotics and Fecal Microbiota Transplant
In recent years, postbiotics (metabiotics, biogenics, or metabolites/cell-free supernatants) have
emerged as a potential instrument to modulate the gut microbiota [188]. They are intracellular soluble
factors secreted by live bacteria as metabolic products or released after bacterial lysis [189].
Postbiotics include enzymes (for example NADH-peroxidase, glutathione peroxidase),
proteins (glutathione), polysaccharides, organic acids (e.g., propionic acid), lipids (SCFA), teichoic acids,
and cell surface proteins. In the majority of cases, postbiotics are derived from Lactobacillus and
Bifidobacterium strains, more seldom from other bacteria such as Streptococcus and Faecalibacterium
species [190]. These soluble factors have demonstrated beneficial effects on the health status, by carrying
out antimicrobial, antioxidant, and immunomodulatory functions, which positively influence the
microbiota composition [191]. Currently, no studies have been conducted to elucidate the effect on
NCD in humans [192]. Animal studies have been conducted, particularly in the poultry industry.
These highlighted the postbiotic power to inhibit pathogens, increase the weight, and ameliorate
microbial composition and inflammatory profile [193,194].
A study by Sokol et al. [195] has demonstrated, in an animal model of Crohn disease, a beneficial
effect induced by the administration of F. prausnitzii or its supernatant on the correction of dysbiosis
and reducing inflammation. A successive study by Cavallari et al. [196] conducted in a murine model
of obesity-induced insulin resistance via IRF4, has demonstrated an increase in insulin sensitivity
following administration of muramyl-dipeptide derived from the bacterial cell wall. The administration
postbiotics derived from lactobacillus was capable to contrast inflammation induced by diseases of the
small intestine or from Salmonella infection in an ex-vivo organ culture model [197].
Postbiotic use represents a valid therapeutic approach in NCDs, as it could improve the
chronic inflammatory status in such pathologies and limit the growth of pathogenic species,
contrasting dysbiosis.
Fecal microbiota transplantation (FMT) is an innovative treatment that is still in an experimental
stage. FMT consists in the administration of a solution containing fecal matter from a healthy
donor to the gastrointestinal tract of the receiving patient, and it is proposed as a useful tool for the
reinstallation of eubiosis [198]. The administration may occur through various methods: nasogastric
tube, nasojejunal tube, esofagastroduodenoscopy, colonoscopy, or enema [199]. To reduce the risk of
transmission of infections or other pathologies, it is fundamental that the donor undergoes rigorous
screening for pathologies with an infectious, neoplastic, metabolic, and autoimmune basis [200]. FMT is
considered safe and well tolerated [201]; however, not completely free of side effects such as abdominal
discomfort, bloating, transient fever, flatulence, constipation, vomiting, and diarrhea [202]. Few studies
are related to the long-term effects of FMT, such as pathologies related to microbiota composition changes
like obesity, DM, neoplasia, asthma, and autism [203]. Therefore, it is essential to perform more studies
with an extensive follow up period post FMT. Currently, the most well-known pathology for which FMT
is effective is severe or recurrent C. difficile infection [204]. Still in a preliminary phase instead, is the
utilization of FMT for the treatment of metabolic, CV, autoimmune, and neurologic conditions [205].
Concerning this, is an important study conducted by Vrieze et al. [206], which demonstrates how
lean donor microbiota infusion determines an increase in insulin sensitivity in metabolic syndrome
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sufferers. Ulterior studies are required in order to validate the efficacy of FMT on pathologies associated
with dysbiosis.
10. Conclusions
Over the last years, the gut microbiota has received increasing interest from scientific literature,
and has started to be considered as a real “new organ”, that influences numerous biological functions of
the organism, such as immunity, digestion, and metabolism. Thanks to new sequencing technologies,
an enormous complexity and a substantial number of potential genes of the microbiota have
been identified. Available clinical and experimental evidence has established the clear role of
the microbiota in chronic NCDs. Initially scientific data was uniquely generated from rodent models,
recently; however, the importance of a healthy gut microbiota is being demonstrated in humans.
Administration of probiotics and prebiotics has been widely used in order to manipulate the gut
microbiota. However, although several studies reported encouraging results, long term efficacy of
this treatment is still being researched. In fact, one of the future challenges relating to the use of
probiotics and prebiotics is linked to producing standardized safety guidelines for the use of these
supplements in humans (particularly in order to determine side effects such as bloating, flatulence,
and generalized gastrointestinal discomfort). Therefore, additional studies and randomized controlled
trials are required for a deeper understanding of the clinical impact of gut microbiota manipulation.
Another interesting and intricate challenge is to understand whether the administration of these
supplements may lead to genetic interactions via genetic exchange between the digested strains and
the indigenous flora, area of research, which remains currently virtually unexplored [207]. For the
future, large prospective cohort studies could provide more evidence and information on clinical
relevance of the microbiota as a potential pathogenic factor for the development of chronic NCDs.
Author Contributions: Conceptualization A.N. and A.R.; writing—original draft preparation: G.M., F.D.D., E.O.
and G.W.J.; review and editing A.N., R.B., A.R. and V.R.
Funding: This research received no external funding.





BMI Body mass index
BP Blood pressure
CK Creatine kinase




DKD Diabetic kidney disease
DM Diabetes mellitus
DMB 3,3-Dimethyl-1-butanol
e-GFR Estimated glomerular filtration rate




F/B Firmicutes to Bacteroides ratio
FAO Food Agricultural Organization
FBG Fasting blood glucose
FBI Fasting blood insulin
FDY Freeze-dried powdered yacon
FetA Fetuin A
FFAs Free fatty acids
FMT Fecal microbiota transplant
FOS Fructooligosaccharides
Nutrients 2019, 11, 1073 24 of 35
GF Germ-free
GLP1 Glucagon-like peptide-1
Gpr41 G protein receptor 41
GSH Glutathione





HFF High fructose fed
HIF Ipoxia-inducible factor
HOMA Homeostasis model assessment of insulin resistance
hs-CRP High-sensitivity C-ractive protein
HT Hydroxytyrosol
HTN Arterial hypertension
IAA Indole 3-acetic acid
Ile-Pro-Pro Isoleucyl–prolyl–proline
IS Indoxyl sulfate
ISAPP International Scientific Association for Probiotics and Prebiotics
K-DOQI Kidney-Disease Outcomes Quality Initiative
KDQOL Kidney Disease Quality of Life
KIM-1 Kidney injury molecule-1
KTR Kidney transplant recipients
L-NAME Nitro-L-arginine methylester





MGWAS Metagenome-wide association study
MHP Microbiome Human Project
NADPH Nicotinamide adenine dinucleotide phosphate
NCD Chronic non-communicable diseases
NEFA Non-esterified fatty acid
NO Nitric oxide






PTC Plasma total cholesterol
QUICKI Quantitative insulin sensitivity check index, determining insulin sensitivity
R Dahl salt-resistant
RCTs Randomized clinical trials
ROS Reactive oxygen species
RS Resistant starch
RSNA Renal sympathetic nerve activity
S Dahl salt-sensitive
SCFAs Short chain fatty acids
SHR Spontaneously hypertensive rats
SIRT1 Sirtuin1
SMAD3 Mothers against decapentaplegic homolog 3
TBARS Thiobarbituric acid reactive species
TG Triglycerides
TGF Transforming growth factor
TIMP1 Metallopeptidase inhibitor 1
TLRs Toll-like receptors
TMAO Trimethylamine-N-oxide
TNF-α Tumor necrosis factor-α
Val-Pro-Pro Valyl–prolyl–proline
VLDL Very-low-density lipoprotein-cholesterol
WBC White blood cell
WHO World Health Organization
Nutrients 2019, 11, 1073 25 of 35
References
1. Qin, J.; Li, R.; Raes, J.; Arumugam, M.; Burgdorf, K.S.; Manichanh, C.; Nielsen, T.; Pons, N.; Levenez, F.;
Yamada, T.; et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature
2010, 464, 59–65. [CrossRef] [PubMed]
2. Rosner, J.L. Ten Times More Microbial Cells than Body Cells in Humans? Microbe 2014, 9, 47. [CrossRef]
3. Sender, R.; Fuchs, S.; Milo, R. Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host
Cells in Humans. Cell 2016, 164, 337–340. [CrossRef]
4. Marchesi, J.R.; Ravel, J. The vocabulary of microbiome research: A proposal. Microbiome 2015, 3, 31.
[CrossRef]
5. The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human
microbiome. Nature 2012, 486, 207–214. [CrossRef]
6. Baquero, F.; Nombela, C. The microbiome as a human organ. Clin. Microbiol. Infect. 2012, 18 (Suppl. 4), 2–4.
[CrossRef]
7. Biagi, E.; Franceschi, C.; Rampelli, S.; Severgnini, M.; Ostan, R.; Turroni, S.; Consolandi, C.; Quercia, S.;
Scurti, M.; Monti, D.; et al. Gut Microbiota and Extreme Longevity. Curr. Biol. 2016, 26, 1480–1485. [CrossRef]
[PubMed]
8. Turnbaugh, P.J.; Ley, R.E.; Hamady, M.; Fraser-Liggett, C.M.; Knight, R.; Gordon, J.I. The human microbiome
project. Nature 2007, 449, 804–810. [CrossRef] [PubMed]
9. Lloyd-Price, J.; Abu-Ali, G.; Huttenhower, C. The healthy human microbiome. Genome Med. 2016, 8, 51.
[CrossRef]
10. Shafquat, A.; Joice, R.; Simmons, S.L.; Huttenhower, C. Functional and phylogenetic assembly of microbial
communities in the human microbiome. Trends Microbiol. 2014, 22, 261–266. [CrossRef]
11. Dominguez-Bello, M.G.; Costello, E.K.; Contreras, M.; Magris, M.; Hidalgo, G.; Fierer, N.; Knight, R.
Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in
newborns. Proc. Natl. Acad. Sci. USA 2010, 107, 11971–11975. [CrossRef] [PubMed]
12. Rodriguez, J.M.; Murphy, K.; Stanton, C.; Ross, R.P.; Kober, O.I.; Juge, N.; Avershina, E.; Rudi, K.; Narbad, A.;
Jenmalm, M.C.; et al. The composition of the gut microbiota throughout life, with an emphasis on early life.
Microb. Ecol. Health Dis. 2015, 26, 26050. [CrossRef] [PubMed]
13. Huurre, A.; Kalliomaki, M.; Rautava, S.; Rinne, M.; Salminen, S.; Isolauri, E. Mode of delivery—Effects on
gut microbiota and humoral immunity. Neonatology 2008, 93, 236–240. [CrossRef]
14. Mountzouris, K.C.; McCartney, A.L.; Gibson, G.R. Intestinal microflora of human infants and current trends
for its nutritional modulation. Br. J. Nutr. 2002, 87, 405–420. [CrossRef]
15. Adlerberth, I. Factors influencing the establishment of the intestinal microbiota in infancy. Nestle Nutr.
Workshop Ser. Pediatr. Progr. 2008, 62, 13–29. [CrossRef]
16. Azad, M.B.; Konya, T.; Maughan, H.; Guttman, D.S.; Field, C.J.; Chari, R.S.; Sears, M.R.; Becker, A.B.;
Scott, J.A.; Kozyrskyj, A.L.; et al. Gut microbiota of healthy Canadian infants: Profiles by mode of delivery
and infant diet at 4 months. CMAJ 2013, 185, 385–394. [CrossRef]
17. Jackson, K.M.; Nazar, A.M. Breastfeeding, the immune response, and long-term health. J. Am. Osteopath. Assoc.
2006, 106, 203–207.
18. Gaulke, C.A.; Sharpton, T.J. The influence of ethnicity and geography on human gut microbiome composition.
Nat. Med. 2018, 24, 1495–1496. [CrossRef]
19. Deschasaux, M.; Bouter, K.E.; Prodan, A.; Levin, E.; Groen, A.K.; Herrema, H.; Tremaroli, V.; Bakker, G.J.;
Attaye, I.; Pinto-Sietsma, S.J.; et al. Depicting the composition of gut microbiota in a population with varied
ethnic origins but shared geography. Nat. Med. 2018, 24, 1526–1531. [CrossRef] [PubMed]
20. Annalisa, N.; Alessio, T.; Claudette, T.D.; Erald, V.; Antonino, D.L.; Nicola, D.D. Gut Microbioma Population:
An Indicator Really Sensible to Any Change in Age, Diet, Metabolic Syndrome, and Life-Style. Mediat. Inflamm.
2014, 2014, 901308. [CrossRef]
21. De Filippo, C.; Cavalieri, D.; Di Paola, M.; Ramazzotti, M.; Poullet, J.B.; Massart, S.; Collini, S.; Pieraccini, G.;
Lionetti, P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe
and rural Africa. Proc. Natl. Acad. Sci. USA 2010, 107, 14691–14696. [CrossRef]
22. Duda-Chodak, A.; Tarko, T.; Satora, P.; Sroka, P. Interaction of dietary compounds, especially polyphenols,
with the intestinal microbiota: A review. Eur. J. Nutr. 2015, 54, 325–341. [CrossRef]
Nutrients 2019, 11, 1073 26 of 35
23. Parkar, S.G.; Stevenson, D.E.; Skinner, M.A. The potential influence of fruit polyphenols on colonic microflora
and human gut health. Int. J. Food Microbiol. 2008, 124, 295–298. [CrossRef]
24. Duda-Chodak, A. The inhibitory effect of polyphenols on human gut microbiota. J. Physiol. Pharmacol.
2012, 63, 497–503.
25. Cory, H.; Passarelli, S.; Szeto, J.; Tamez, M.; Mattei, J. The Role of Polyphenols in Human Health and Food
Systems: A Mini-Review. Front. Nutr. 2018, 5, 87. [CrossRef] [PubMed]
26. Cianci, R.; Pagliari, D.; Piccirillo, C.A.; Fritz, J.H.; Gambassi, G. The Microbiota and Immune System Crosstalk
in Health and Disease. Mediat. Inflamm. 2018, 2018, 2912539. [CrossRef]
27. Cote, C.D.; Rasmussen, B.A.; Duca, F.A.; Zadeh-Tahmasebi, M.; Baur, J.A.; Daljeet, M.; Breen, D.M.;
Filippi, B.M.; Lam, T.K. Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through
a neuronal network. Nat. Med. 2015, 21, 498–505. [CrossRef] [PubMed]
28. Sung, M.M.; Kim, T.T.; Denou, E.; Soltys, C.M.; Hamza, S.M.; Byrne, N.J.; Masson, G.; Park, H.; Wishart, D.S.;
Madsen, K.L.; et al. Improved Glucose Homeostasis in Obese Mice Treated with Resveratrol Is Associated
with Alterations in the Gut Microbiome. Diabetes 2017, 66, 418–425. [CrossRef]
29. Liao, W.; Yin, X.; Li, Q.; Zhang, H.; Liu, Z.; Zheng, X.; Zheng, L.; Feng, X. Resveratrol-Induced White Adipose
Tissue Browning in Obese Mice by Remodeling Fecal Microbiota. Molecules 2018, 23, 3356. [CrossRef]
30. Qiao, Y.; Sun, J.; Xia, S.; Tang, X.; Shi, Y.; Le, G. Effects of resveratrol on gut microbiota and fat storage in
a mouse model with high-fat-induced obesity. Food Funct. 2014, 5, 1241–1249. [CrossRef]
31. Crovesy, L.; Ostrowski, M.; Ferreira, D.; Rosado, E.L.; Soares-Mota, M. Effect of Lactobacillus on body weight
and body fat in overweight subjects: A systematic review of randomized controlled clinical trials. Int. J. Obes.
2017, 41, 1607–1614. [CrossRef] [PubMed]
32. Dao, M.C.; Everard, A.; Aron-Wisnewsky, J.; Sokolovska, N.; Prifti, E.; Verger, E.O.; Kayser, B.D.; Levenez, F.;
Chilloux, J.; Hoyles, L.; et al. Akkermansia muciniphila and improved metabolic health during a dietary
intervention in obesity: Relationship with gut microbiome richness and ecology. Gut 2016, 65, 426–436.
[CrossRef] [PubMed]
33. Ahmadi, S.; Mainali, R.; Nagpal, R.; Sheikh-Zeinoddin, M.; Soleimanian-Zad, S.; Wang, S.; Deep, G.;
Kumar Mishra, S.; Yadav, H. Dietary Polysaccharides in the Amelioration of Gut Microbiome Dysbiosis and
Metabolic Diseases. Obes. Control. Ther. 2017, 4. [CrossRef]
34. Cheng, W.; Lu, J.; Li, B.; Lin, W.; Zhang, Z.; Wei, X.; Sun, C.; Chi, M.; Bi, W.; Yang, B.; et al. Effect of Functional
Oligosaccharides and Ordinary Dietary Fiber on Intestinal Microbiota Diversity. Front. Microbiol. 2017, 8, 1750.
[CrossRef] [PubMed]
35. Peyrol, J.; Riva, C.; Amiot, M.J. Hydroxytyrosol in the Prevention of the Metabolic Syndrome and Related
Disorders. Nutrients 2017, 9, 306. [CrossRef]
36. Possemiers, S.; Bolca, S.; Verstraete, W.; Heyerick, A. The intestinal microbiome: A separate organ inside
the body with the metabolic potential to influence the bioactivity of botanicals. Fitoterapia 2011, 82, 53–66.
[CrossRef]
37. Koenig, J.E.; Spor, A.; Scalfone, N.; Fricker, A.D.; Stombaugh, J.; Knight, R.; Angenent, L.T.; Ley, R.E.
Succession of microbial consortia in the developing infant gut microbiome. Proc. Natl. Acad. Sci. USA
2011, 108 (Suppl. 1), 4578–4585. [CrossRef]
38. Zapata, H.J.; Quagliarello, V.J. The microbiota and microbiome in aging: Potential implications in health and
age-related diseases. J. Am. Geriatr. Soc. 2015, 63, 776–781. [CrossRef]
39. Lofmark, S.; Jernberg, C.; Jansson, J.K.; Edlund, C. Clindamycin-induced enrichment and long-term
persistence of resistant Bacteroides spp. and resistance genes. J. Antimicrob. Chemother. 2006, 58, 1160–1167.
[CrossRef]
40. Clarke, S.F.; Murphy, E.F.; O’Sullivan, O.; Lucey, A.J.; Humphreys, M.; Hogan, A.; Hayes, P.; O’Reilly, M.;
Jeffery, I.B.; Wood-Martin, R.; et al. Exercise and associated dietary extremes impact on gut microbial diversity.
Gut 2014, 63, 1913–1920. [CrossRef]
41. Prehn-Kristensen, A.; Zimmermann, A.; Tittmann, L.; Lieb, W.; Schreiber, S.; Baving, L.; Fischer, A.
Reduced microbiome alpha diversity in young patients with ADHD. PLoS ONE 2018, 13, e0200728. [CrossRef]
[PubMed]
42. Karlsson, C.L.; Onnerfalt, J.; Xu, J.; Molin, G.; Ahrne, S.; Thorngren-Jerneck, K. The microbiota of the gut
in preschool children with normal and excessive body weight. Obesity 2012, 20, 2257–2261. [CrossRef]
[PubMed]
Nutrients 2019, 11, 1073 27 of 35
43. Everard, A.; Belzer, C.; Geurts, L.; Ouwerkerk, J.P.; Druart, C.; Bindels, L.B.; Guiot, Y.; Derrien, M.;
Muccioli, G.G.; Delzenne, N.M.; et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium
controls diet-induced obesity. Proc. Natl. Acad. Sci. USA 2013, 110, 9066–9071. [CrossRef] [PubMed]
44. Ottman, N.; Geerlings, S.Y.; Aalvink, S.; de Vos, W.M.; Belzer, C. Action and function of Akkermansia
muciniphila in microbiome ecology, health and disease. Best Pract. Res. Clin. Gastroenterol. 2017, 31, 637–642.
[CrossRef] [PubMed]
45. Derrien, M.; Vaughan, E.E.; Plugge, C.M.; de Vos, W.M. Akkermansia muciniphila gen. nov., sp. nov., a human
intestinal mucin-degrading bacterium. Int. J. Syst. Evol. Microbiol. 2004, 54, 1469–1476. [CrossRef] [PubMed]
46. Turnbaugh, P.J.; Ley, R.E.; Mahowald, M.A.; Magrini, V.; Mardis, E.R.; Gordon, J.I. An obesity-associated gut
microbiome with increased capacity for energy harvest. Nature 2006, 444, 1027–1031. [CrossRef]
47. Arumugam, M.; Raes, J.; Pelletier, E.; Le Paslier, D.; Yamada, T.; Mende, D.R.; Fernandes, G.R.; Tap, J.;
Bruls, T.; Batto, J.M.; et al. Enterotypes of the human gut microbiome. Nature 2011, 473, 174–180. [CrossRef]
[PubMed]
48. Wu, G.D.; Chen, J.; Hoffmann, C.; Bittinger, K.; Chen, Y.Y.; Keilbaugh, S.A.; Bewtra, M.; Knights, D.;
Walters, W.A.; Knight, R.; et al. Linking long-term dietary patterns with gut microbial enterotypes. Science
2011, 334, 105–108. [CrossRef] [PubMed]
49. Knights, D.; Ward, T.L.; McKinlay, C.E.; Miller, H.; Gonzalez, A.; McDonald, D.; Knight, R.
Rethinking “enterotypes”. Cell Host Microbe 2014, 16, 433–437. [CrossRef]
50. Jeffery, I.B.; Claesson, M.J.; O’Toole, P.W.; Shanahan, F. Categorization of the gut microbiota: Enterotypes or
gradients? Nat. Rev. Microbiol. 2012, 10, 591–592. [CrossRef]
51. Clemente, J.C.; Ursell, L.K.; Parfrey, L.W.; Knight, R. The impact of the gut microbiota on human health:
An integrative view. Cell 2012, 148, 1258–1270. [CrossRef] [PubMed]
52. Zuo, T.; Ng, S.C. The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease.
Front. Microbiol. 2018, 9, 2247. [CrossRef]
53. Nguyen, T.L.; Vieira-Silva, S.; Liston, A.; Raes, J. How informative is the mouse for human gut microbiota
research? Dis. Model. Mech. 2015, 8, 1–16. [CrossRef]
54. Eckburg, P.B.; Bik, E.M.; Bernstein, C.N.; Purdom, E.; Dethlefsen, L.; Sargent, M.; Gill, S.R.; Nelson, K.E.;
Relman, D.A. Diversity of the human intestinal microbial flora. Science 2005, 308, 1635–1638. [CrossRef]
55. Ley, R.E.; Backhed, F.; Turnbaugh, P.; Lozupone, C.A.; Knight, R.D.; Gordon, J.I. Obesity alters gut microbial
ecology. Proc. Natl. Acad. Sci. USA 2005, 102, 11070–11075. [CrossRef]
56. Ley, R.E.; Turnbaugh, P.J.; Klein, S.; Gordon, J.I. Microbial ecology: Human gut microbes associated with
obesity. Nature 2006, 444, 1022–1023. [CrossRef]
57. Einheber, A.; Carter, D. The role of the microbial flora in uremia. I. Survival times of germfree, limited-flora,
and conventionalized rats after bilateral nephrectomy and fasting. J. Exp. Med. 1966, 123, 239–250. [CrossRef]
58. Aronov, P.A.; Luo, F.J.; Plummer, N.S.; Quan, Z.; Holmes, S.; Hostetter, T.H.; Meyer, T.W. Colonic contribution
to uremic solutes. J. Am. Soc. Nephrol. 2011, 22, 1769–1776. [CrossRef] [PubMed]
59. Vaziri, N.D.; Wong, J.; Pahl, M.; Piceno, Y.M.; Yuan, J.; DeSantis, T.Z.; Ni, Z.; Nguyen, T.H.; Andersen, G.L.
Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013, 83, 308–315. [CrossRef]
60. Rowland, I.; Gibson, G.; Heinken, A.; Scott, K.; Swann, J.; Thiele, I.; Tuohy, K. Gut microbiota functions:
Metabolism of nutrients and other food components. Eur. J. Nutr. 2018, 57, 1–24. [CrossRef] [PubMed]
61. Pluznick, J.L. Gut microbiota in renal physiology: Focus on short-chain fatty acids and their receptors.
Kidney Int. 2016, 90, 1191–1198. [CrossRef]
62. Sokol, H.; Seksik, P.; Furet, J.P.; Firmesse, O.; Nion-Larmurier, I.; Beaugerie, L.; Cosnes, J.; Corthier, G.;
Marteau, P.; Dore, J. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm. Bowel Dis.
2009, 15, 1183–1189. [CrossRef]
63. Chang, P.V.; Hao, L.; Offermanns, S.; Medzhitov, R. The microbial metabolite butyrate regulates intestinal
macrophage function via histone deacetylase inhibition. Proc. Natl. Acad. Sci. USA 2014, 111, 2247–2252.
[CrossRef] [PubMed]
64. Dessi, M.; Noce, A.; Agnoli, A.; De Angelis, S.; Fuiano, L.; Tozzo, C.; Taccone-Gallucci, M.; Fuiano, G.;
Federici, G. The usefulness of the prognostic inflammatory and nutritional index (PINI) in a haemodialysis
population. Nutr. Metab. Cardiovasc. Dis. 2009, 19, 811–815. [CrossRef] [PubMed]
Nutrients 2019, 11, 1073 28 of 35
65. Missailidis, C.; Hallqvist, J.; Qureshi, A.R.; Barany, P.; Heimburger, O.; Lindholm, B.; Stenvinkel, P.; Bergman, P.
Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic
Kidney Disease. PLoS ONE 2016, 11, e0141738. [CrossRef] [PubMed]
66. Tang, W.H.; Wang, Z.; Levison, B.S.; Koeth, R.A.; Britt, E.B.; Fu, X.; Wu, Y.; Hazen, S.L. Intestinal microbial
metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 2013, 368, 1575–1584. [CrossRef]
[PubMed]
67. Stubbs, J.R.; House, J.A.; Ocque, A.J.; Zhang, S.; Johnson, C.; Kimber, C.; Schmidt, K.; Gupta, A.; Wetmore, J.B.;
Nolin, T.D.; et al. Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary
Atherosclerosis Burden. J. Am. Soc. Nephrol. 2016, 27, 305–313. [CrossRef]
68. Tang, W.H.; Wang, Z.; Kennedy, D.J.; Wu, Y.; Buffa, J.A.; Agatisa-Boyle, B.; Li, X.S.; Levison, B.S.; Hazen, S.L.
Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of
renal insufficiency and mortality risk in chronic kidney disease. Circ. Res. 2015, 116, 448–455. [CrossRef]
69. Kim, R.B.; Morse, B.L.; Djurdjev, O.; Tang, M.; Muirhead, N.; Barrett, B.; Holmes, D.T.; Madore, F.; Clase, C.M.;
Rigatto, C.; et al. Advanced chronic kidney disease populations have elevated trimethylamine N-oxide
levels associated with increased cardiovascular events. Kidney Int. 2016, 89, 1144–1152. [CrossRef] [PubMed]
70. Sun, G.; Yin, Z.; Liu, N.; Bian, X.; Yu, R.; Su, X.; Zhang, B.; Wang, Y. Gut microbial metabolite TMAO
contributes to renal dysfunction in a mouse model of diet-induced obesity. Biochem. Biophys. Res. Commun.
2017, 493, 964–970. [CrossRef] [PubMed]
71. Watanabe, H.; Miyamoto, Y.; Otagiri, M.; Maruyama, T. Update on the pharmacokinetics and redox properties
of protein-bound uremic toxins. J. Pharm. Sci. 2011, 100, 3682–3695. [CrossRef] [PubMed]
72. Miyazaki, T.; Ise, M.; Seo, H.; Niwa, T. Indoxyl sulfate increases the gene expressions of TGF-beta 1, TIMP-1
and pro-alpha 1(I) collagen in uremic rat kidneys. Kidney Int. Suppl. 1997, 62, S15–S22.
73. Barreto, F.C.; Barreto, D.V.; Liabeuf, S.; Meert, N.; Glorieux, G.; Temmar, M.; Choukroun, G.; Vanholder, R.;
Massy, Z.A.; European Uremic Toxin Work Group. Serum indoxyl sulfate is associated with vascular disease
and mortality in chronic kidney disease patients. Clin. J. Am. Soc. Nephrol. 2009, 4, 1551–1558. [CrossRef]
[PubMed]
74. Watanabe, H.; Miyamoto, Y.; Honda, D.; Tanaka, H.; Wu, Q.; Endo, M.; Noguchi, T.; Kadowaki, D.; Ishima, Y.;
Kotani, S.; et al. p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation
of NADPH oxidase. Kidney Int. 2013, 83, 582–592. [CrossRef] [PubMed]
75. Bammens, B.; Evenepoel, P.; Keuleers, H.; Verbeke, K.; Vanrenterghem, Y. Free serum concentrations of the
protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int. 2006, 69, 1081–1087.
[CrossRef]
76. Anders, H.J.; Andersen, K.; Stecher, B. The intestinal microbiota, a leaky gut, and abnormal immunity in
kidney disease. Kidney Int. 2013, 83, 1010–1016. [CrossRef] [PubMed]
77. Fernandez-Prado, R.; Esteras, R.; Perez-Gomez, M.V.; Gracia-Iguacel, C.; Gonzalez-Parra, E.; Sanz, A.B.;
Ortiz, A.; Sanchez-Nino, M.D. Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties
in Chronic Kidney Disease. Nutrients 2017, 9, 489. [CrossRef]
78. Alam, U.; Asghar, O.; Azmi, S.; Malik, R.A. General aspects of diabetes mellitus. Handb. Clin. Neurol.
2014, 126, 211–222. [CrossRef] [PubMed]
79. Cani, P.D.; Amar, J.; Iglesias, M.A.; Poggi, M.; Knauf, C.; Bastelica, D.; Neyrinck, A.M.; Fava, F.; Tuohy, K.M.;
Chabo, C.; et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56, 1761–1772.
[CrossRef] [PubMed]
80. Noce, A.; Fabrini, R.; Dessi, M.; Bocedi, A.; Santini, S.; Rovella, V.; Pastore, A.; Tesauro, M.; Bernardini, S.;
Di Daniele, N.; et al. Erythrocyte glutathione transferase activity: A possible early biomarker for blood
toxicity in uremic diabetic patients. Acta Diabetol. 2014, 51, 219–224. [CrossRef]
81. Di Daniele, N.; Noce, A.; Vidiri, M.F.; Moriconi, E.; Marrone, G.; Annicchiarico-Petruzzelli, M.; D’Urso, G.;
Tesauro, M.; Rovella, V.; De Lorenzo, A. Impact of Mediterranean diet on metabolic syndrome, cancer and
longevity. Oncotarget 2017, 8, 8947–8979. [CrossRef] [PubMed]
82. Boulange, C.L.; Neves, A.L.; Chilloux, J.; Nicholson, J.K.; Dumas, M.E. Impact of the gut microbiota on
inflammation, obesity, and metabolic disease. Genome Med. 2016, 8, 42. [CrossRef] [PubMed]
83. Cani, P.D.; Knauf, C.; Iglesias, M.A.; Drucker, D.J.; Delzenne, N.M.; Burcelin, R. Improvement of glucose
tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1
receptor. Diabetes 2006, 55, 1484–1490. [CrossRef]
Nutrients 2019, 11, 1073 29 of 35
84. Ingalls, A.M.; Dickie, M.M.; Snell, G.D. Obese, a new mutation in the house mouse. J. Hered. 1950, 41, 317–318.
[CrossRef]
85. Membrez, M.; Blancher, F.; Jaquet, M.; Bibiloni, R.; Cani, P.D.; Burcelin, R.G.; Corthesy, I.; Mace, K.; Chou, C.J.
Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J.
2008, 22, 2416–2426. [CrossRef]
86. Schneeberger, M.; Everard, A.; Gomez-Valades, A.G.; Matamoros, S.; Ramirez, S.; Delzenne, N.M.; Gomis, R.;
Claret, M.; Cani, P.D. Akkermansia muciniphila inversely correlates with the onset of inflammation,
altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci. Rep. 2015, 5, 16643.
[CrossRef] [PubMed]
87. Creely, S.J.; McTernan, P.G.; Kusminski, C.M.; Fisher f, M.; Da Silva, N.F.; Khanolkar, M.; Evans, M.;
Harte, A.L.; Kumar, S. Lipopolysaccharide activates an innate immune system response in human adipose
tissue in obesity and type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 2007, 292, E740–E747. [CrossRef]
88. Amar, J.; Serino, M.; Lange, C.; Chabo, C.; Iacovoni, J.; Mondot, S.; Lepage, P.; Klopp, C.; Mariette, J.;
Bouchez, O.; et al. Involvement of tissue bacteria in the onset of diabetes in humans: Evidence for a concept.
Diabetologia 2011, 54, 3055–3061. [CrossRef]
89. Woo, P.C.; Lau, S.K.; Teng, J.L.; Tse, H.; Yuen, K.Y. Then and now: Use of 16S rDNA gene
sequencing for bacterial identification and discovery of novel bacteria in clinical microbiology laboratories.
Clin. Microbiol. Infect. 2008, 14, 908–934. [CrossRef]
90. Zhang, X.; Shen, D.; Fang, Z.; Jie, Z.; Qiu, X.; Zhang, C.; Chen, Y.; Ji, L. Human gut microbiota changes reveal
the progression of glucose intolerance. PLoS ONE 2013, 8, e71108. [CrossRef]
91. Qin, J.; Li, Y.; Cai, Z.; Li, S.; Zhu, J.; Zhang, F.; Liang, S.; Zhang, W.; Guan, Y.; Shen, D.; et al. A metagenome-wide
association study of gut microbiota in type 2 diabetes. Nature 2012, 490, 55–60. [CrossRef]
92. Karlsson, F.H.; Tremaroli, V.; Nookaew, I.; Bergstrom, G.; Behre, C.J.; Fagerberg, B.; Nielsen, J.; Backhed, F.
Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013, 498, 99–103.
[CrossRef] [PubMed]
93. Hansen, T.H.; Gobel, R.J.; Hansen, T.; Pedersen, O. The gut microbiome in cardio-metabolic health.
Genome Med. 2015, 7, 33. [CrossRef] [PubMed]
94. Yang, T.; Santisteban, M.M.; Rodriguez, V.; Li, E.; Ahmari, N.; Carvajal, J.M.; Zadeh, M.; Gong, M.; Qi, Y.;
Zubcevic, J.; et al. Gut dysbiosis is linked to hypertension. Hypertension 2015, 65, 1331–1340. [CrossRef]
95. Adnan, S.; Nelson, J.W.; Ajami, N.J.; Venna, V.R.; Petrosino, J.F.; Bryan, R.M., Jr.; Durgan, D.J. Alterations in
the gut microbiota can elicit hypertension in rats. Physiol. Genom. 2017, 49, 96–104. [CrossRef] [PubMed]
96. Mell, B.; Jala, V.R.; Mathew, A.V.; Byun, J.; Waghulde, H.; Zhang, Y.; Haribabu, B.; Vijay-Kumar, M.;
Pennathur, S.; Joe, B. Evidence for a link between gut microbiota and hypertension in the Dahl rat.
Physiol. Genom. 2015, 47, 187–197. [CrossRef] [PubMed]
97. Pluznick, J.L.; Protzko, R.J.; Gevorgyan, H.; Peterlin, Z.; Sipos, A.; Han, J.; Brunet, I.; Wan, L.X.; Rey, F.;
Wang, T.; et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion
and blood pressure regulation. Proc. Natl. Acad. Sci. USA 2013, 110, 4410–4415. [CrossRef] [PubMed]
98. Li, J.; Zhao, F.; Wang, Y.; Chen, J.; Tao, J.; Tian, G.; Wu, S.; Liu, W.; Cui, Q.; Geng, B.; et al. Gut microbiota
dysbiosis contributes to the development of hypertension. Microbiome 2017, 5, 14. [CrossRef]
99. Hill, C.; Guarner, F.; Reid, G.; Gibson, G.R.; Merenstein, D.J.; Pot, B.; Morelli, L.; Canani, R.B.; Flint, H.J.;
Salminen, S.; et al. Expert consensus document. The International Scientific Association for Probiotics
and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev.
Gastroenterol. Hepatol. 2014, 11, 506–514. [CrossRef]
100. Kopple, J.D. National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal
failure. Am. J. Kidney Dis. 2001, 37, S66–S70. [CrossRef] [PubMed]
101. Cruz, M.C.; Andrade, C.; Urrutia, M.; Draibe, S.; Nogueira-Martins, L.A.; Sesso Rde, C. Quality of life in
patients with chronic kidney disease. Clinics 2011, 66, 991–995. [CrossRef]
102. Miranda Alatriste, P.V.; Urbina Arronte, R.; Gomez Espinosa, C.O.; Espinosa Cuevas Mde, L. Effect of
probiotics on human blood urea levels in patients with chronic renal failure. Nutr. Hosp. 2014, 29, 582–590.
[CrossRef]
103. Miraghajani, M.; Zaghian, N.; Dehkohneh, A.; Mirlohi, M.; Ghiasvand, R. Probiotic Soy Milk Consumption
and Renal Function Among Type 2 Diabetic Patients with Nephropathy: A Randomized Controlled Clinical
Trial. Probiotics Antimicrob. Proteins 2019, 11, 124–132. [CrossRef] [PubMed]
Nutrients 2019, 11, 1073 30 of 35
104. Le Barz, M.; Anhe, F.F.; Varin, T.V.; Desjardins, Y.; Levy, E.; Roy, D.; Urdaci, M.C.; Marette, A. Probiotics as
Complementary Treatment for Metabolic Disorders. Diabetes Metab. J. 2015, 39, 291–303. [CrossRef]
105. Yadav, H.; Jain, S.; Sinha, P.R. Effect of skim milk and dahi (yogurt) on blood glucose, insulin, and lipid
profile in rats fed with high fructose diet. J. Med. Food 2006, 9, 328–335. [CrossRef] [PubMed]
106. Thorburn, A.W.; Storlien, L.H.; Jenkins, A.B.; Khouri, S.; Kraegen, E.W. Fructose-induced in vivo insulin
resistance and elevated plasma triglyceride levels in rats. Am. J. Clin. Nutr. 1989, 49, 1155–1163. [CrossRef]
[PubMed]
107. Yadav, H.; Jain, S.; Sinha, P.R. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and
Lactobacillus casei in high fructose fed rats. Nutrition 2007, 23, 62–68. [CrossRef] [PubMed]
108. Parvez, S.; Malik, K.A.; Ah Kang, S.; Kim, H.Y. Probiotics and their fermented food products are beneficial
for health. J. Appl. Microbiol. 2006, 100, 1171–1185. [CrossRef]
109. Upadrasta, A.; Madempudi, R.S. Probiotics and blood pressure: Current insights. Integr. Blood Press. Control
2016, 9, 33–42. [CrossRef]
110. Mauriello, A.; Rovella, V.; Anemona, L.; Servadei, F.; Giannini, E.; Bove, P.; Anselmo, A.; Melino, G.;
Di Daniele, N. Increased Sympathetic Renal Innervation in Hemodialysis Patients Is the Anatomical Substrate
of Sympathetic Hyperactivity in End-Stage Renal Disease. J. Am. Heart Assoc. 2015, 4. [CrossRef]
111. Biancardi, V.C.; Bomfim, G.F.; Reis, W.L.; Al-Gassimi, S.; Nunes, K.P. The interplay between Angiotensin II,
TLR4 and hypertension. Pharmacol. Res. 2017, 120, 88–96. [CrossRef] [PubMed]
112. Xu, J.; Ahren, I.L.; Prykhodko, O.; Olsson, C.; Ahrne, S.; Molin, G. Intake of Blueberry Fermented by
Lactobacillus plantarum Affects the Gut Microbiota of L-NAME Treated Rats. Evid. Based Complement.
Altern. Med. 2013, 2013, 809128. [CrossRef]
113. Nakamura, Y.; Yamamoto, N.; Sakai, K.; Okubo, A.; Yamazaki, S.; Takano, T. Purification and characterization
of angiotensin I-converting enzyme inhibitors from sour milk. J. Dairy Sci. 1995, 78, 777–783. [CrossRef]
114. Jauhiainen, T.; Vapaatalo, H.; Poussa, T.; Kyronpalo, S.; Rasmussen, M.; Korpela, R. Lactobacillus
helveticus fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory blood
pressure measurement. Am. J. Hypertens. 2005, 18, 1600–1605. [CrossRef] [PubMed]
115. Metchnikoff, E. The Prolongation of Life: Optimistic Studies; Mitchell, P.C., Ed.; G P Putnam’s Sons:
New York, NY, USA, 1910; 96p.
116. He, M.; Shi, B. Gut microbiota as a potential target of metabolic syndrome: The role of probiotics and
prebiotics. Cell Biosci. 2017, 7, 54. [CrossRef] [PubMed]
117. Wang, I.K.; Wu, Y.Y.; Yang, Y.F.; Ting, I.W.; Lin, C.C.; Yen, T.H.; Chen, J.H.; Wang, C.H.; Huang, C.C.;
Lin, H.C. The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients:
A randomised, double-blind, placebo-controlled trial. Benef. Microbes 2015, 6, 423–430. [CrossRef]
118. Stenvinkel, P.; Ketteler, M.; Johnson, R.J.; Lindholm, B.; Pecoits-Filho, R.; Riella, M.; Heimburger, O.;
Cederholm, T.; Girndt, M. IL-10, IL-6, and TNF-alpha: Central factors in the altered cytokine network of
uremia—The good, the bad, and the ugly. Kidney Int. 2005, 67, 1216–1233. [CrossRef]
119. Kimmel, P.L.; Phillips, T.M.; Simmens, S.J.; Peterson, R.A.; Weihs, K.L.; Alleyne, S.; Cruz, I.; Yanovski, J.A.;
Veis, J.H. Immunologic function and survival in hemodialysis patients. Kidney Int. 1998, 54, 236–244.
[CrossRef]
120. Hauser, A.B.; Stinghen, A.E.; Goncalves, S.M.; Bucharles, S.; Pecoits-Filho, R. A gut feeling on endotoxemia:
Causes and consequences in chronic kidney disease. Nephron Clin. Pract. 2011, 118, c165–c172. [CrossRef]
121. Vitetta, L.; Linnane, A.W.; Gobe, G.C. From the gastrointestinal tract (GIT) to the kidneys: Live bacterial cultures
(probiotics) mediating reductions of uremic toxin levels via free radical signaling. Toxins 2013, 5, 2042–2057. [CrossRef]
122. Ranganathan, N.; Patel, B.; Ranganathan, P.; Marczely, J.; Dheer, R.; Chordia, T.; Dunn, S.R.; Friedman, E.A.
Probiotic amelioration of azotemia in 5/6th nephrectomized Sprague-Dawley rats. Sci. World J. 2005, 5, 652–660.
[CrossRef] [PubMed]
123. Ranganathan, N.; Ranganathan, P.; Friedman, E.A.; Joseph, A.; Delano, B.; Goldfarb, D.S.; Tam, P.; Rao, A.V.;
Anteyi, E.; Musso, C.G. Pilot study of probiotic dietary supplementation for promoting healthy kidney
function in patients with chronic kidney disease. Adv. Ther. 2010, 27, 634–647. [CrossRef]
124. Natarajan, R.; Pechenyak, B.; Vyas, U.; Ranganathan, P.; Weinberg, A.; Liang, P.; Mallappallil, M.C.; Norin, A.J.;
Friedman, E.A.; Saggi, S.J. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in
dialysis patients. Biomed. Res. Int. 2014, 2014, 568571. [CrossRef]
Nutrients 2019, 11, 1073 31 of 35
125. Ranganathan, N.; Patel, B.G.; Ranganathan, P.; Marczely, J.; Dheer, R.; Pechenyak, B.; Dunn, S.R.; Verstraete, W.;
Decroos, K.; Mehta, R.; et al. In vitro and in vivo assessment of intraintestinal bacteriotherapy in chronic
kidney disease. ASAIO J. 2006, 52, 70–79. [CrossRef] [PubMed]
126. Chiang, C.K.; Tanaka, T.; Inagi, R.; Fujita, T.; Nangaku, M. Indoxyl sulfate, a representative uremic toxin,
suppresses erythropoietin production in a HIF-dependent manner. Lab. Investig. 2011, 91, 1564–1571.
[CrossRef]
127. Wu, C.J.; Chen, C.Y.; Lai, T.S.; Wu, P.C.; Chuang, C.K.; Sun, F.J.; Liu, H.L.; Chen, H.H.; Yeh, H.I.; Lin, C.S.; et al. The role
of indoxyl sulfate in renal anemia in patients with chronic kidney disease. Oncotarget 2017, 8, 83030–83037. [CrossRef]
[PubMed]
128. Asai, H.; Hirata, J.; Watanabe-Akanuma, M. Indoxyl glucuronide, a protein-bound uremic toxin,
inhibits hypoxia-inducible factordependent erythropoietin expression through activation of aryl hydrocarbon
receptor. Biochem. Biophys. Res. Commun. 2018, 504, 538–544. [CrossRef]
129. National Kidney, F. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification,
and stratification. Am. J. Kidney Dis 2002, 39, S1–266.
130. Miraghajani, M.; Zaghian, N.; Mirlohi, M.; Feizi, A.; Ghiasvand, R. The Impact of Probiotic Soy Milk
Consumption on Oxidative Stress Among Type 2 Diabetic Kidney Disease Patients: A Randomized
Controlled Clinical Trial. J. Ren. Nutr. 2017, 27, 317–324. [CrossRef] [PubMed]
131. Kumawat, M.; Sharma, T.K.; Singh, I.; Singh, N.; Ghalaut, V.S.; Vardey, S.K.; Shankar, V. Antioxidant Enzymes
and Lipid Peroxidation in Type 2 Diabetes Mellitus Patients with and without Nephropathy. N. Am. J. Med.
Sci. 2013, 5, 213–219. [CrossRef]
132. Tiwari, B.K.; Pandey, K.B.; Abidi, A.B.; Rizvi, S.I. Markers of Oxidative Stress during Diabetes Mellitus.
J. Biomark. 2013, 2013, 378790. [CrossRef] [PubMed]
133. Jha, J.C.; Banal, C.; Chow, B.S.; Cooper, M.E.; Jandeleit-Dahm, K. Diabetes and Kidney Disease: Role of
Oxidative Stress. Antioxid. Redox Signal. 2016, 25, 657–684. [CrossRef] [PubMed]
134. Nasri, H.; Ardalan, M.R.; Rafieian-Kopaei, M. Mechanistic Impacts of Medicinal Plants in Diabetic Kidney
Disease. Iran. J. Public Health 2014, 43, 1311–1313.
135. Borges, N.A.; Carmo, F.L.; Stockler-Pinto, M.B.; de Brito, J.S.; Dolenga, C.J.; Ferreira, D.C.; Nakao, L.S.;
Rosado, A.; Fouque, D.; Mafra, D. Probiotic Supplementation in Chronic Kidney Disease: A Double-blind,
Randomized, Placebo-controlled Trial. J. Ren. Nutr. 2018, 28, 28–36. [CrossRef] [PubMed]
136. Tejero-Sarinena, S.; Barlow, J.; Costabile, A.; Gibson, G.R.; Rowland, I. In vitro evaluation of the antimicrobial activity
of a range of probiotics against pathogens: Evidence for the effects of organic acids. Anaerobe 2012, 18, 530–538.
[CrossRef]
137. Oksaharju, A.; Kooistra, T.; Kleemann, R.; van Duyvenvoorde, W.; Miettinen, M.; Lappalainen, J.;
Lindstedt, K.A.; Kovanen, P.T.; Korpela, R.; Kekkonen, R.A. Effects of probiotic Lactobacillus rhamnosus GG
and Propionibacterium freudenreichii ssp. shermanii JS supplementation on intestinal and systemic markers of
inflammation in ApoE*3Leiden mice consuming a high-fat diet. Br. J. Nutr. 2013, 110, 77–85. [CrossRef]
138. Khalili, L.; Alipour, B.; Asghari Jafar-Abadi, M.; Faraji, I.; Hassanalilou, T.; Mesgari Abbasi, M.;
Vaghef-Mehrabany, E.; Alizadeh Sani, M. The Effects of Lactobacillus casei on Glycemic Response,
Serum Sirtuin1 and Fetuin-A Levels in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled
Trial. Iran. Biomed. J. 2019, 23, 68–77. [CrossRef]
139. Firouzi, S.; Mohd-Yusof, B.N.; Majid, H.A.; Ismail, A.; Kamaruddin, N.A. Effect of microbial cell preparation
on renal profile and liver function among type 2 diabetics: A randomized controlled trial. BMC Complement.
Altern. Med. 2015, 15, 433. [CrossRef] [PubMed]
140. Vaziri, N.D. CKD impairs barrier function and alters microbial flora of the intestine: A major link to
inflammation and uremic toxicity. Curr. Opin. Nephrol. Hypertens. 2012, 21, 587–592. [CrossRef] [PubMed]
141. Kijmanawat, A.; Panburana, P.; Reutrakul, S.; Tangshewinsirikul, C. Effects of probiotic supplements on insulin
resistance in gestational diabetes mellitus: A double-blind randomized controlled trial. J. Diabetes Investig.
2019, 10, 163–170. [CrossRef]
142. De Brito Alves, J.L.; de Sousa, V.P.; Cavalcanti Neto, M.P.; Magnani, M.; Braga, V.A.; da Costa-Silva, J.H.;
Leandro, C.G.; Vidal, H.; Pirola, L. New Insights on the Use of Dietary Polyphenols or Probiotics for the
Management of Arterial Hypertension. Front. Physiol. 2016, 7, 448. [CrossRef] [PubMed]
Nutrients 2019, 11, 1073 32 of 35
143. Tanida, M.; Yamano, T.; Maeda, K.; Okumura, N.; Fukushima, Y.; Nagai, K. Effects of intraduodenal injection
of Lactobacillus johnsonii La1 on renal sympathetic nerve activity and blood pressure in urethane-anesthetized
rats. Neurosci. Lett. 2005, 389, 109–114. [CrossRef]
144. Grassi, G.; Mark, A.; Esler, M. The sympathetic nervous system alterations in human hypertension. Circ. Res.
2015, 116, 976–990. [CrossRef] [PubMed]
145. Rovella, V.; Scimeca, M.; Giannini, E.; D’Ercole, A.; Giacobbi, E.; Noce, A.; D’Urso, G.; Anselmo, A.; Bove, P.;
Santeusanio, G.; et al. Morphological evaluation of sympathetic renal innervation in patients with autosomal
dominant polycystic kidney disease. J. Nephrol. 2019. [CrossRef] [PubMed]
146. Gomez-Guzman, M.; Toral, M.; Romero, M.; Jimenez, R.; Galindo, P.; Sanchez, M.; Zarzuelo, M.J.; Olivares, M.;
Galvez, J.; Duarte, J. Antihypertensive effects of probiotics Lactobacillus strains in spontaneously hypertensive
rats. Mol. Nutr. Food Res. 2015, 59, 2326–2336. [CrossRef] [PubMed]
147. Singh, M.V.; Cicha, M.Z.; Nunez, S.; Meyerholz, D.K.; Chapleau, M.W.; Abboud, F.M. Angiotensin II-induced
hypertension and cardiac hypertrophy are differentially mediated by TLR3- and TLR4-dependent pathways.
Am. J. Physiol. Heart Circ. Physiol. 2019, 316, H1027–H1038. [CrossRef] [PubMed]
148. Ahren, I.L.; Xu, J.; Onning, G.; Olsson, C.; Ahrne, S.; Molin, G. Antihypertensive activity of blueberries
fermented by Lactobacillus plantarum DSM 15313 and effects on the gut microbiota in healthy rats. Clin. Nutr.
2015, 34, 719–726. [CrossRef]
149. Tuomilehto, J.; Lindstrom, J.; Hyyrynen, J.; Korpela, R.; Karhunen, M.L.; Mikkola, L.; Jauhiainen, T.; Seppo, L.;
Nissinen, A. Effect of ingesting sour milk fermented using Lactobacillus helveticus bacteria producing
tripeptides on blood pressure in subjects with mild hypertension. J. Hum. Hypertens. 2004, 18, 795–802.
[CrossRef]
150. Blood Pressure Lowering Treatment Trialists’ Collaboration; Ninomiya, T.; Perkovic, V.; Turnbull, F.; Neal, B.;
Barzi, F.; Cass, A.; Baigent, C.; Chalmers, J.; Li, N.; et al. Blood pressure lowering and major cardiovascular
events in people with and without chronic kidney disease: Meta-analysis of randomised controlled trials.
BMJ 2013, 347, f5680. [CrossRef]
151. Aoyagi, Y.; Park, S.; Matsubara, S.; Honda, Y.; Amamoto, R.; Kushiro, A.; Miyazaki, K.; Shephard, R.J.
Habitual intake of fermented milk products containing Lactobacillus casei strain Shirota and a reduced risk of
hypertension in older people. Benef. Microbes 2017, 8, 23–29. [CrossRef]
152. Furushiro, M.; Hashimoto, S.; Hamura, M.; Yokokura, T. Mechanism for the antihypertensive effect of
a polysaccharide-glycopeptide complex from Lactobacillus casei in spontaneously hypertensive rats (SHR).
Biosci. Biotechnol. Biochem. 1993, 57, 978–981. [CrossRef] [PubMed]
153. Gibson, G.R.; Roberfroid, M.B. Dietary modulation of the human colonic microbiota: Introducing the concept
of prebiotics. J. Nutr. 1995, 125, 1401–1412. [CrossRef]
154. Hutkins, R.W.; Krumbeck, J.A.; Bindels, L.B.; Cani, P.D.; Fahey, G., Jr.; Goh, Y.J.; Hamaker, B.; Martens, E.C.;
Mills, D.A.; Rastal, R.A.; et al. Prebiotics: Why definitions matter. Curr. Opin. Biotechnol. 2016, 37, 1–7.
[CrossRef]
155. Pineiro, M.; Asp, N.G.; Reid, G.; Macfarlane, S.; Morelli, L.; Brunser, O.; Tuohy, K. FAO Technical meeting on
prebiotics. J. Clin. Gastroenterol. 2008, 42, S156–S159. [CrossRef]
156. Slavin, J. Fiber and prebiotics: Mechanisms and health benefits. Nutrients 2013, 5, 1417–1435. [CrossRef]
[PubMed]
157. De Lorenzo, A.; Noce, A.; Bigioni, M.; Calabrese, V.; Della Rocca, D.G.; Di Daniele, N.; Tozzo, C.; Di Renzo, L.
The effects of Italian Mediterranean organic diet (IMOD) on health status. Curr. Pharm. Des. 2010, 16, 814–824.
[CrossRef]
158. Di Daniele, N.; Di Renzo, L.; Noce, A.; Iacopino, L.; Ferraro, P.M.; Rizzo, M.; Sarlo, F.; Domino, E.;
De Lorenzo, A. Effects of Italian Mediterranean organic diet vs. low-protein diet in nephropathic patients
according to MTHFR genotypes. J. Nephrol. 2014, 27, 529–536. [CrossRef]
159. Ramos, C.I.; Armani, R.G.; Canziani, M.E.F.; Dalboni, M.A.; Dolenga, C.J.R.; Nakao, L.S.; Campbell, K.L.;
Cuppari, L. Effect of prebiotic (fructooligosaccharide) on uremic toxins of chronic kidney disease patients:
A randomized controlled trial. Nephrol. Dial. Transplant. 2018. [CrossRef] [PubMed]
160. Dou, L.; Sallee, M.; Cerini, C.; Poitevin, S.; Gondouin, B.; Jourde-Chiche, N.; Fallague, K.; Brunet, P.; Calaf, R.;
Dussol, B.; et al. The cardiovascular effect of the uremic solute indole-3 acetic acid. J. Am. Soc. Nephrol.
2015, 26, 876–887. [CrossRef] [PubMed]
Nutrients 2019, 11, 1073 33 of 35
161. Vanholder, R.; Abou-Deif, O.; Argiles, A.; Baurmeister, U.; Beige, J.; Brouckaert, P.; Brunet, P.; Cohen, G.;
De Deyn, P.P.; Drueke, T.B.; et al. The role of EUTox in uremic toxin research. Semin. Dial. 2009, 22, 323–328.
[CrossRef]
162. Noce, A.; Ferrannini, M.; Fabrini, R.; Bocedi, A.; Dessi, M.; Galli, F.; Federici, G.; Palumbo, R.; Di Daniele, N.;
Ricci, G. Erythrocyte glutathione transferase: A new biomarker for hemodialysis adequacy, overcoming the
Kt/V(urea) dogma? Cell Death Dis. 2012, 3, e377. [CrossRef] [PubMed]
163. Poesen, R.; Evenepoel, P.; de Loor, H.; Delcour, J.A.; Courtin, C.M.; Kuypers, D.; Augustijns, P.; Verbeke, K.; Meijers, B.
The Influence of Prebiotic Arabinoxylan Oligosaccharides on Microbiota Derived Uremic Retention Solutes in
Patients with Chronic Kidney Disease: A Randomized Controlled Trial. PLoS ONE 2016, 11, e0153893. [CrossRef]
164. Everard, A.; Lazarevic, V.; Derrien, M.; Girard, M.; Muccioli, G.G.; Neyrinck, A.M.; Possemiers, S.;
Van Holle, A.; Francois, P.; de Vos, W.M.; et al. Responses of gut microbiota and glucose and lipid metabolism
to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 2011, 60, 2775–2786. [CrossRef]
[PubMed]
165. Dinarello, C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117, 3720–3732.
[CrossRef]
166. Bodinham, C.L.; Smith, L.; Thomas, E.L.; Bell, J.D.; Swann, J.R.; Costabile, A.; Russell-Jones, D.; Umpleby, A.M.;
Robertson, M.D. Efficacy of increased resistant starch consumption in human type 2 diabetes. Endocr. Connect.
2014, 3, 75–84. [CrossRef] [PubMed]
167. Aliasgharzadeh, A.; Dehghan, P.; Gargari, B.P.; Asghari-Jafarabadi, M. Resistant dextrin, as a prebiotic,
improves insulin resistance and inflammation in women with type 2 diabetes: A randomised controlled
clinical trial. Br. J. Nutr. 2015, 113, 321–330. [CrossRef]
168. Lefranc-Millot, C.; Guerin-Deremaux, L.; Wils, D.; Neut, C.; Miller, L.E.; Saniez-Degrave, M.H. Impact of
a resistant dextrin on intestinal ecology: How altering the digestive ecosystem with NUTRIOSE(R), a soluble
fibre with prebiotic properties, may be beneficial for health. J. Int. Med. Res. 2012, 40, 211–224. [CrossRef]
169. Marques, F.Z.; Nelson, E.; Chu, P.Y.; Horlock, D.; Fiedler, A.; Ziemann, M.; Tan, J.K.; Kuruppu, S.; Rajapakse, N.W.;
El-Osta, A.; et al. High-Fiber Diet and Acetate Supplementation Change the Gut Microbiota and Prevent the
Development of Hypertension and Heart Failure in Hypertensive Mice. Circulation 2017, 135, 964–977. [CrossRef]
[PubMed]
170. Noce, A.; Vidiri, M.F.; Marrone, G.; Moriconi, E.; Bocedi, A.; Capria, A.; Rovella, V.; Ricci, G.; De Lorenzo, A.;
Di Daniele, N. Is low-protein diet a possible risk factor of malnutrition in chronic kidney disease patients?
Cell Death Discov. 2016, 2, 16026. [CrossRef]
171. Cupisti, A.; Brunori, G.; Di Iorio, B.R.; D’Alessandro, C.; Pasticci, F.; Cosola, C.; Bellizzi, V.; Bolasco, P.;
Capitanini, A.; Fantuzzi, A.L.; et al. Nutritional treatment of advanced CKD: Twenty consensus statements.
J. Nephrol. 2018, 31, 457–473. [CrossRef]
172. Younes, H.; Egret, N.; Hadj-Abdelkader, M.; Remesy, C.; Demigne, C.; Gueret, C.; Deteix, P.; Alphonse, J.C.
Fermentable carbohydrate supplementation alters nitrogen excretion in chronic renal failure. J. Ren. Nutr.
2006, 16, 67–74. [CrossRef]
173. Meijers, B.K.; De Preter, V.; Verbeke, K.; Vanrenterghem, Y.; Evenepoel, P. p-Cresyl sulfate serum concentrations
in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol. Dial. Transplant.
2010, 25, 219–224. [CrossRef]
174. Sirich, T.L.; Plummer, N.S.; Gardner, C.D.; Hostetter, T.H.; Meyer, T.W. Effect of increasing dietary fiber on
plasma levels of colon-derived solutes in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2014, 9, 1603–1610.
[CrossRef]
175. Dehghan, P.; Pourghassem Gargari, B.; Asghari Jafar-abadi, M. Oligofructose-enriched inulin improves some
inflammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: A randomized
controlled clinical trial. Nutrition 2014, 30, 418–423. [CrossRef] [PubMed]
176. Andreoli, A.; Lauro, S.; Di Daniele, N.; Sorge, R.; Celi, M.; Volpe, S.L. Effect of a moderately hypoenergetic
Mediterranean diet and exercise program on body cell mass and cardiovascular risk factors in obese women.
Eur. J. Clin. Nutr. 2008, 62, 892–897. [CrossRef] [PubMed]
177. Yang, J.Y.; Lee, Y.S.; Kim, Y.; Lee, S.H.; Ryu, S.; Fukuda, S.; Hase, K.; Yang, C.S.; Lim, H.S.; Kim, M.S.;
et al. Gut commensal Bacteroides acidifaciens prevents obesity and improves insulin sensitivity in mice.
Mucosal Immunol. 2017, 10, 104–116. [CrossRef] [PubMed]
Nutrients 2019, 11, 1073 34 of 35
178. Xiao, S.; Fei, N.; Pang, X.; Shen, J.; Wang, L.; Zhang, B.; Zhang, M.; Zhang, X.; Zhang, C.; Li, M.; et al. A gut
microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic
syndrome. FEMS Microbiol. Ecol. 2014, 87, 357–367. [CrossRef]
179. Rault-Nania, M.H.; Demougeot, C.; Gueux, E.; Berthelot, A.; Dzimira, S.; Rayssiguier, Y.; Rock, E.; Mazur, A. Inulin
supplementation prevents high fructose diet-induced hypertension in rats. Clin. Nutr. 2008, 27, 276–282. [CrossRef]
180. Hsu, C.N.; Lin, Y.J.; Hou, C.Y.; Tain, Y.L. Maternal Administration of Probiotic or Prebiotic Prevents Male
Adult Rat Offspring against Developmental Programming of Hypertension Induced by High Fructose
Consumption in Pregnancy and Lactation. Nutrients 2018, 10, 1229. [CrossRef]
181. Pena, A.S. Intestinal flora, probiotics, prebiotics, symbiotics and novel foods. Rev. Esp. Enferm. Dig. 2007, 99, 653–658.
182. Pandey, K.R.; Naik, S.R.; Vakil, B.V. Probiotics, prebiotics and synbiotics—A review. J. Food Sci. Technol.
2015, 52, 7577–7587. [CrossRef] [PubMed]
183. Eslamparast, T.; Zamani, F.; Hekmatdoost, A.; Sharafkhah, M.; Eghtesad, S.; Malekzadeh, R.; Poustchi, H.
Effects of synbiotic supplementation on insulin resistance in subjects with the metabolic syndrome:
A randomised, double-blind, placebo-controlled pilot study. Br. J. Nutr. 2014, 112, 438–445. [CrossRef]
[PubMed]
184. Ahmadi, S.; Jamilian, M.; Tajabadi-Ebrahimi, M.; Jafari, P.; Asemi, Z. The effects of synbiotic supplementation
on markers of insulin metabolism and lipid profiles in gestational diabetes: A randomised, double-blind,
placebo-controlled trial. Br. J. Nutr. 2016, 116, 1394–1401. [CrossRef] [PubMed]
185. Pavan, M. Influence of prebiotic and probiotic supplementation on the progression of chronic kidney disease.
Minerva Urol. Nefrol. 2016, 68, 222–226.
186. Guida, B.; Cataldi, M.; Memoli, A.; Trio, R.; di Maro, M.; Grumetto, L.; Capuano, I.; Federico, S.; Pisani, A.;
Sabbatini, M. Effect of a Short-Course Treatment with Synbiotics on Plasma p-Cresol Concentration in Kidney
Transplant Recipients. J. Am. Coll. Nutr. 2017, 36, 586–591. [CrossRef]
187. Viramontes-Horner, D.; Marquez-Sandoval, F.; Martin-del-Campo, F.; Vizmanos-Lamotte, B.;
Sandoval-Rodriguez, A.; Armendariz-Borunda, J.; Garcia-Bejarano, H.; Renoirte-Lopez, K.; Garcia-Garcia, G.
Effect of a symbiotic gel (Lactobacillus acidophilus + Bifidobacterium lactis + inulin) on presence and severity
of gastrointestinal symptoms in hemodialysis patients. J. Ren. Nutr. 2015, 25, 284–291. [CrossRef]
188. Avolio, E.; Gualtieri, P.; Romano, L.; Pecorella, C.; Ferraro, S.; Di Renzo, L.; De Lorenzo, A. Obesity and body
composition in man and woman: Associated diseases and new role of gut microbiota. Curr. Med. Chem.
2019, 26. [CrossRef]
189. Cicenia, A.; Scirocco, A.; Carabotti, M.; Pallotta, L.; Marignani, M.; Severi, C. Postbiotic activities of
lactobacilli-derived factors. J. Clin. Gastroenterol. 2014, 48 (Suppl. 1), S18–S22. [CrossRef]
190. Konstantinov, S.R.; Kuipers, E.J.; Peppelenbosch, M.P. Functional genomic analyses of the gut microbiota for
CRC screening. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 741–745. [CrossRef]
191. Shenderov, B.A. Metabiotics: Novel idea or natural development of probiotic conception. Microb. Ecol.
Health Dis. 2013, 24, 20399. [CrossRef]
192. Cosola, C.; Rocchetti, M.T.; Cupisti, A.; Gesualdo, L. Microbiota metabolites: Pivotal players of cardiovascular
damage in chronic kidney disease. Pharmacol. Res. 2018, 130, 132–142. [CrossRef] [PubMed]
193. Kareem, K.Y.; Hooi Ling, F.; Teck Chwen, L.; May Foong, O.; Anjas Asmara, S. Inhibitory activity of
postbiotic produced by strains of Lactobacillus plantarum using reconstituted media supplemented with
inulin. Gut Pathog. 2014, 6, 23. [CrossRef]
194. Kareem, K.Y.; Loh, T.C.; Foo, H.L.; Asmara, S.A.; Akit, H. Influence of postbiotic RG14 and inulin combination
on cecal microbiota, organic acid concentration, and cytokine expression in broiler chickens. Poult. Sci.
2017, 96, 966–975. [CrossRef]
195. Sokol, H.; Pigneur, B.; Watterlot, L.; Lakhdari, O.; Bermudez-Humaran, L.G.; Gratadoux, J.J.; Blugeon, S.;
Bridonneau, C.; Furet, J.P.; Corthier, G.; et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal
bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. USA
2008, 105, 16731–16736. [CrossRef]
196. Cavallari, J.F.; Fullerton, M.D.; Duggan, B.M.; Foley, K.P.; Denou, E.; Smith, B.K.; Desjardins, E.M.;
Henriksbo, B.D.; Kim, K.J.; Tuinema, B.R.; et al. Muramyl Dipeptide-Based Postbiotics Mitigate
Obesity-Induced Insulin Resistance via IRF4. Cell Metab. 2017, 25, 1063–1074.e3. [CrossRef]
Nutrients 2019, 11, 1073 35 of 35
197. Tsilingiri, K.; Barbosa, T.; Penna, G.; Caprioli, F.; Sonzogni, A.; Viale, G.; Rescigno, M. Probiotic and postbiotic activity
in health and disease: Comparison on a novel polarised ex-vivo organ culture model. Gut 2012, 61, 1007–1015.
[CrossRef]
198. Smits, L.P.; Bouter, K.E.; de Vos, W.M.; Borody, T.J.; Nieuwdorp, M. Therapeutic potential of fecal microbiota
transplantation. Gastroenterology 2013, 145, 946–953. [CrossRef]
199. Gough, E.; Shaikh, H.; Manges, A.R. Systematic review of intestinal microbiota transplantation (fecal
bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis. 2011, 53, 994–1002. [CrossRef]
[PubMed]
200. Kelly, B.J.; Tebas, P. Clinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for
Clostridium difficile Infection. Chest 2018, 153, 266–277. [CrossRef] [PubMed]
201. Borody, T.J.; Khoruts, A. Fecal microbiota transplantation and emerging applications. Nat. Rev.
Gastroenterol. Hepatol. 2011, 9, 88–96. [CrossRef]
202. Kassam, Z.; Lee, C.H.; Yuan, Y.; Hunt, R.H. Fecal microbiota transplantation for Clostridium difficile infection:
Systematic review and meta-analysis. Am. J. Gastroenterol. 2013, 108, 500–508. [CrossRef] [PubMed]
203. Kelly, C.R.; Kahn, S.; Kashyap, P.; Laine, L.; Rubin, D.; Atreja, A.; Moore, T.; Wu, G. Update on Fecal
Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology
2015, 149, 223–237. [CrossRef] [PubMed]
204. Choi, H.H.; Cho, Y.S. Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future
Perspectives. Clin. Endosc. 2016, 49, 257–265. [CrossRef]
205. Sadowsky, M.J.; Khoruts, A. Faecal microbiota transplantation is promising but not a panacea. Nat. Microbiol.
2016, 1, 16015. [CrossRef]
206. Vrieze, A.; Van Nood, E.; Holleman, F.; Salojarvi, J.; Kootte, R.S.; Bartelsman, J.F.; Dallinga-Thie, G.M.;
Ackermans, M.T.; Serlie, M.J.; Oozeer, R.; et al. Transfer of intestinal microbiota from lean donors increases
insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012, 143, 913–916.e7. [CrossRef]
[PubMed]
207. Yoo, J.Y.; Kim, S.S. Probiotics and Prebiotics: Present Status and Future Perspectives on Metabolic Disorders.
Nutrients 2016, 8, 173. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
